Conditions: Advanced Renal Cell Carcinoma
Keywords: Nivolumab Ipilimumab OPDIVO IgG1 kappa immunoglobulin
Allocation: NON_RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 164
Healthy volunteers: no

Brief summary:
Phase II trial of nivolumab in 120 treatment naïve patients with ccRCC.

Detailed description:
Eligible patients with biopsiable (biopsied) disease will receive nivolumab 240 mg IV every 2 weeks x 6 doses then 360 mg every 3 weeks for up to 84 weeks. Tumor response will be assessed at weeks 12, 18 and 24 and then every 12 weeks. For patients who experience RECIST 1.1 defined PD, but remain clinically stable (and asymptomatic), a confirmatory scan after 6 weeks (± 1 week) of additional therapy is suggested. Patients with persistent PD at confirmatory scan will be evaluated for enrollment on Part B of this study. Symptomatic patients may be evaluated for Part B immediately. Patients without confirmed PD can continue on nivolumab therapy.

Patients who experience symptomatic or confirmed PD (or have best response of SD at 12 months) on nivolumab monotherapy will be eligible for consideration for Part B. Part B involves the addition of ipilimumab for up to 4 doses while maintaining nivolumab therapy. Dose of ipilimumab will be 1 mg/kg every 3 weeks together with nivolumab changed to 3 mg/kg every 3 weeks for up to 4 doses. Nivolumab will revert to 360 mg every 3 weeks after the completion of treatment with ipilimumab (beginning week 13-19 of Part B) for up to 48 weeks. Patients will be followed with serial imaging assessments weeks 12, 18 and 24 and then every 12 weeks after the initiation of ipilimumab. The tumor measurements at the time of ipilimumab institution will be the new baseline. If unequivocal symptomatic or confirmed new PD (as defined above) develops, treatment will be discontinued.

Patients for Part B must still meet the eligibility criteria for initial study enrollment. Patients with Grade 3 toxicity on nivolumab monotherapy, serious symptomatic disease that in the opinion of the site investigator requires immediate use of an alternative treatment approach or continued PR/CR will be excluded from enrolling in Part B. It is estimated that roughly half of the patients accrued to the first-line treatment will go on to enroll in Part B.

An additional biopsy will be performed of a metastatic lesion at time of confirmed PD in all patients enrolling in Part B. Confirmation of tumor in the biopsy specimen must occur prior to initiation of treatment on Part B. FFPE and frozen tissue will be stored from this sample and used for correlative studies described below.

An additional cohort of 40 non-ccRCC patients will be enrolled and analyzed separately for evidence of anti-tumor activity (CR, PR and SD and PFS at 1 year of nivolumab). These patients will also be eligible for participation in Part B. We anticipate that the accrual of these 40 patients will be able to be completed within the 1.5 years needed for accrual of the ccRCC patients.

Part A: Nivolumab Administration. Nivolumab will be given every 2 weeks x 6 at a dose of 240 mg Intravenously (IV) and then every 3 weeks at a dose of 360 mg IV until toxicity, complete response, disease progression, SD at 12 months or a maximum of 96 total weeks (12 weeks induction, 84 weeks maintenance) Patients with disease progression (at any time) or SD at 12 months will be eligible to be considered for participation in Part B of the study.

Part B: Nivolumab + Ipilimumab. Patients with Grade 3 toxicity on nivolumab monotherapy, (excluding endocrine toxicity), serious symptomatic disease that in the opinion of the site investigator requires immediate use of an alternative treatment approach or continued PR/CR will be excluded from enrolling in Part B. It is estimated that roughly half of the patients accrued to the first line treatment will go on to enroll in Part B.

Ipilimumab will be given 1 mg/kg every 3 weeks together with nivolumab 240 mg every 3 weeks for up to 4 doses. Nivolumab will revert to 3 mg/kg every 3 weeks after the completion of combination treatment with ipilimumab .

Following the first 4 doses of the combination of nivolumab and ipilimumab, nivolumab monotherapy will again be given every 3 weeks at a dose of 360 mg for a maximum of 48 weeks. Patients may be dosed no less than 18 days from the previous dose of drug; and dosed up to 3 days after the scheduled date, if necessary.

Arms:
arm 1: Nivolumab 240mg; Nivolumab 360mg arm 2: Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg

Interventions: intervention 1: Nivolumab 240 mg intervention 2: Ipilimumab 1mg/kg intervention 3: Nivolumab 3mg/kg intervention 4: Nivolumab 360mg
Intervention descriptions: intervention 1: PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment intervention 2: Ipilimumab 1 mg/kg every 3 weeks x 4 intervention 3: In combination with Ipilimumab intervention 4: Continue Nivolumab 360 mg IV every 3 weeks

Protocol document:
Prot_SAP_000.pdf: 
Clinical Study Protocol 
HCRN GU16-260 
 
Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in 
patients with advanced renal cell carcinoma HCRN: GU16-260 
 
Sponsor Investigator 
Michael B. Atkins, MD 
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center 
3970 Reservoir Road NW Research Building, Room E501 Washington, DC  20057 
Phone: (202) 687-2795 
Fax: (202) 687-1370  
Email: mba41@Georgetown.edu 
 
Co-Investigators 
Geoffrey T. Gibney, MD 
MedStar Georgetown University Hospital 
3800 Reservoir Rd, NW Washington DC, 
20057 
Geoffrey.T.Gibney@gunet.georgetown.edu 
 
Hans Hammers, MD, PhD 
UT Southwestern Medical Center 
6001 Forest Park Rd, ND3.120B, Dallas, TX 
75390-8852 
Hans.Hammers@utsouthwestern.edu 
 
David F. McDermott, MD 
Beth Israel Deaconess Medical Center 
350 Longwood Ave, Rm 412 Boston, MA 
02215 
Phone (617) 632-9250 
Dmcdermo@bidmc.harvard.edu 
 
Sabina Signoretti, MD 
Department of Pathology 
Brigham and Women’s Hospital Boston, 
MA 
 
Statistician 
Paul Catalano, ScD 
Department of Biostatistics and Computational Biology 
Dana-Farber Cancer Institute Boston MA  
 
 
Trial Supported by  
Bristol-Myers Squibb Company (BMS) 
BMS Protocol # CA209-669 
 
 
Trial Management Provided by  
Hoosier Cancer Research Network, Inc. 
7676 Interactive Way Suite 120 
Indianapolis, IN 46278
 
Investigational New Drug (IND) # 133893 
 
 
Initial Protocol Version Date: 05FEB2017 
Protocol Amendment Version Date:  
28MAR2017 
15DEC2017 
02JUL2018 
16NOV2018 
14MAY2020 
25MAR2021 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 2 of 71 
PROTOCOL SIGNATURE PAGE 
 
Study Title: Phase II study of front line therapy with nivolumab and salvage nivolumab + 
ipilimumab in patients with advanced renal cell carcinoma 
 
 
VERSION DATE:  25MAR2021 
I confirm I have read this protocol, I understand it, and I will work according to this protocol and 
to the ethical principles stated in the latest version of the Declaration of Helsinki, the applicable 
guidelines for good clinical practices, whichever provides the greater protection of the 
individual. I will accept the monitor’s overseeing of the study. I will promptly submit the 
protocol to applicable institutional review board(s). 
 
 
 
 
____________________________________ 
________________________ 
 Signature of Site Investigator 
 
 
  
 Date 
 
 
____________________________________ 
 Site Investigator Name (printed) 
 
 
____________________________________ 
 Site Investigator Title 
 
 
____________________________________ 
 Name of Facility 
 
 
____________________________________ 
 Location of Facility (City and State) 
 
 
 
 PLEASE COMPLETE AND EMAIL A COPY TO HCRN 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 3 of 71 
SYNOPSIS 
TITLE 
Study Title: Phase II study of front line therapy with nivolumab 
and salvage nivolumab + ipilimumab in patients with advanced 
renal cell carcinoma 
PHASE  
II 
BACKGROUND 
AND 
SIGNIFICANCE 
Renal Cell Carcinoma (RCC) is the most common malignant lesion 
of the kidney, with an estimated annual incidence in the U.S. of 
over 50,000 new cases and 13,000 deaths per year. With currently 
available treatments, the median overall survival is around 28 
months.  
 
First-line treatment for clear cell RCC typically involves vascular 
endothelial growth factor receptor (VEGFR) tyrosine kinase 
inhibitors (TKIs) sunitinib or pazopanib. Additional agents for 
second-line therapy have included alternative VEGFR TKIs (e.g. 
axitinib), the mTOR inhibitor everolimus as well as agents active 
against multiple tyrosine kinases. Recently both nivolumab an anti-
PD1 based immunotherapy (see below) and cabozantinib a TKI 
targeting both VEGFR and Met, have shown OS benefits relative to 
mTOR inhibition in patients with prior VEGRF TKI therapy 
resulting in their FDA approval.  
 
Nivolumab in the treatment of RCC. Preclincal and clinical studies 
have identified critical mechanisms by which cancers subvert 
normal immunomodulatory mechanisms (referred to as 
“checkpoints”) to block the initiation, delivery, or activation of 
effective anti-tumor surveillance. These insights have led to the 
development of a new class of immunotherapeutics referred to as 
“checkpoint inhibitors,” which include nivolumab, a human IgG4 
monoclonal antibody that binds to the programmed death receptor-1 
(PD-1) and blocks its interaction with PD-L1 and PD-L2, releasing 
PD-1 pathway-mediated inhibition of the immune response, 
including the anti-tumor immune response.  
 
Nivolumab was approved in November 2015 by the US FDA for 
use in patients with advanced RCC who have received prior 
VEGFR TKI therapy.  The approval was based on a randomized 
(1:1) open-label study of nivolumab or everolimus. Nivolumab 
demonstrated a statistically significant improvement in overall 
survival (OS) compared to everolimus, with a median survival of 
25.0 vs. 19.6 months (hazard ratio 0.73, p<0.002) and confirmed 
objective response rates of 21.5% vs 3.9%, respectively.  In 
addition, grade 3 toxicity was significantly less and quality of life 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 4 of 71 
significantly improved in patients treated with nivolumab relative to 
those receiving everolimus. 
 
The OS benefit, history of durable responses and tolerability of 
nivolumab suggest that it be a preferred treatment for a subset of 
treatment naïve patients. However, currently there is very limited 
single agent data on the activity of nivolumab in treatment naïve 
patients with ccRCC. The BMS-sponsored study CA 209009 
included 23 subjects with treatment-naïve RCC. In these patients, 
treatment with nivolumab 10 mg/kg every 3 weeks resulted in an 
overall response rate of 13% (3/23).   
 
Further anti-PD1/PDL1 therapies have shown anti-tumor activity in 
patients with over 20 different types of malignancy; however only 
anecdotal reports exist for this treatment approach in patients with 
non-clear cell (ncc)RCC.    
 
Finally, the combination of nivolumab and the CTLA4 checkpoint 
inhibitor ipilimumab has produced greater antitumor activity than 
nivolumab alone in patients with advanced melanoma and 
encouraging response rates in patients with ccRCC.  It remains 
uncertain whether the addition of ipilimumab to nivolumab in 
patients who have failed to respond to nivolumab monotherapy 
could produce antitumor activity. To address all these concerns, we 
propose to conduct a study of nivolumab monotherapy in treatment 
naïve patients with advanced cc or nccRCC (Part A), with the 
addition of ipilimumab in patients with disease progression or who 
have failed to respond by 48 weeks into therapy (Part B) that will 
focus on uncovering biomarkers of response and resistance to PD-1 
blockade, as well as possible predictors of subsequent response to 
CTLA-4 blockade. 
 
In this trial, we examine the following questions: 
1) How active is PD-1 blockade in treatment naïve kidney cancer?  
2) What factors, in addition to PD-L1 expression, can reliably 
predict durable response?  
3) Do gene expression signatures which are likely capturing the 
presence, magnitude, and activity of adaptive immune infiltrates 
reliably predict durable response?  
4) Is there a threshold for PD-L1 expression in either the tumor or 
immune cell infiltrate that accurately predicts durable response?  
5) Is PD-L1 expression uniform and stable in an individual tumor 
and between a primary tumor and its metastases?  
6) What are the mechanisms of innate resistance to PD-1 pathway 
blockade?   


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 5 of 71 
7) Can the addition of ipilimumab overcome resistance and/or 
enhance response it patients with prolonged stable disease? 
8) Do gene expression analyses of biopsies in PD1 resistant tumors 
predict the response to ipilimumab/nivolumab combination 
therapy? 
OBJECTIVES 
Primary Objective: 
Determine the PFS rate at 1 year of nivolumab in patients with 
treatment naïve ccRCC based on tumor PD-L1 expression. 
 
Secondary Objectives: 
 Determine the PFS rate at 1 year- by both RECIST and 
irRECIST of nivolumab in patients with treatment naïve 
ccRCC based on the PD1- Blockade Durable Response 
Predictive (PRP) biomarker model developed in the 
DFHCC Kidney Cancer SPORE 
 Determine the objective response rate (CR/PR=ORR), the 
ORR based on PDL1 expression and the PRP model, and 
duration of response for nivolumab in patients with 
treatment naïve ccRCC 
 Determine the response rate of combined nivolumab and 
ipilimumab therapy at the time of nivolumab failure (or lack 
of response at 1 year) 
 Determine the clinical activity (CR, PR and SD) and PFS 
rate at 1 year of nivolumab in patients with treatment naive 
nccRCC 
 Assess the toxicity of nivolumab monotherapy in patients 
with treatment naïve cc or nccRCC 
 
Correlative Objectives: 
 Explore novel potential predictive biomarkers for patients 
with treatment naïve ccRCC and nccRCC 
 Explore the mechanisms of innate and acquired resistance to 
nivolumab therapy in treatment naïve patients with ccRCC 
 Identify biomarkers associated with response to nivolumab 
+ ipilimumab in patients whose disease has not responded 
or progressed on nivolumab monotherapy 
STUDY DESIGN 
The study will be a prospective Phase II trial of nivolumab in 134 
treatment naïve patients with clear cell (cc)RCC and 40 treatment 
naïve patients with non-clear cell (ncc)RCC. Eligible patients with 
tumor tissue available will receive nivolumab 240 mg flat dose IV 
q 2 weeks for 12 weeks then every 3 weeks at a dose of 360 mg IV 
for 12 weeks followed by nivolumab 480 mg IV every 4 weeks.  
Tumor response will be assessed at weeks 12, 18 and 24 and then 
every 12 weeks.  For patients who experience RECIST defined 
PD, but remain clinically asymptomatic with maintenance of 
performance status, a confirmatory scan after 4-6 weeks of 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 6 of 71 
additional therapy is suggested. Patients with persistent PD at 
confirmatory scan will be evaluated for enrollment on Part B of 
this study.  Patients without confirmed PD can continue nivolumab 
therapy.  Patients with symptomatic and radiographic PD will not 
require a confirmatory scan before proceeding to Part B of this 
study. Adverse events will be recorded continuously. 
 
Patients who experience symptomatic or confirmed PD (or have 
best response of SD at 48 weeks) on nivolumab monotherapy will 
be eligible for consideration for Part B (ipilimumab/nivolumab re-
induction). Part B involves the addition of ipilimumab for up to 4 
doses while maintaining nivolumab therapy. Dose of ipilimumab 
will be 1 mg/kg every 3 weeks together with nivolumab changed 
to 3 mg/kg every 3 weeks for up to 4 doses (must complete by 
week 16). Nivolumab will revert to 360 mg every 3 weeks for 12 
weeks followed by nivolumab 480 mg IV every 4 weeks after the 
completion of treatment with ipilimumab (beginning week 13-19 
of Part B).  Patients will continue to be followed with serial 
imaging assessments 12, 18 and 24 weeks after the initiation of 
ipilimumab (Part B) and then every 12 weeks.  The tumor 
measurements at the time of ipilimumab institution will be the new 
baseline.  If unequivocal symptomatic or confirmed new PD (as 
defined above) develops, treatment will be discontinued.  Patients 
for Part B must still meet the eligibility criteria for initial study 
enrollment.  Patients with Grade 3 toxicity on nivolumab 
monotherapy, (excluding endocrine toxicity), serious symptomatic 
disease that in the opinion of the site investigator requires 
immediate use of an alternative treatment approach or continued 
PR/CR will be excluded from enrolling in Part B.  It is estimated 
that roughly half of the patients accrued to the first line treatment 
will go on to enroll in Part B. 
 
KEY 
ELIGIBILITY 
CRITERIA (See 
Section 3 for full 
eligibility criteria) 
Part A 
1. Patients must have advanced RCC (any histology) 
Collecting duct tumors and tumors originating from the 
renal pelvis or upper urinary tract are considered of 
urothelial origin and are excluded from this protocol.   
2. Patients must have at least one measurable site of disease 
that has not been previously irradiated. If the patient has 
had previous radiation to the marker lesion(s), there must 
be evidence of progression since the radiation 
3. Archival tissue of a metastatic lesion obtained within 1 year 
prior to study registration (within 4 weeks preferred) and 
tumor tissue from nephrectomy is required if available.  In 
addition to archival tissue of a metastatic lesion and 
nephrectomy, patients must have at least one site of disease 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 7 of 71 
(not including bone metastases) accessible for biopsy.  If 
biopsy/resection of a new lesion or primary tumor and slow 
freezing of fresh tissue for single cell RNAseq study (as 
specified in the CLM) is not feasible, the subject is not 
eligible for the study. All biopsies must be core needle or 
excisional. Fine needle aspirate is not acceptable. NOTE: 
The tissue collected from a surgical resection or multiple 
core biopsies of either a metastatic lesion or primary tumor 
for the slow freezing of fresh tissue after the patient has 
signed consent for the study could also be used for 
collecting the FFPE specimens. 
4. ECOG performance status 0-2 
5.  Age ≥ 18 years 
6. Patients must have adequate organ and marrow function 
within 14 days prior to study entry  
7. Patients with controlled brain metastases are allowed on 
protocol if they have had brain metastases that were 
surgically resected without recurrence and/or up to 3 
metastases treated with SRS without progression on MRI 
obtained at least 2 weeks after completion of radiation and 
within 28 days prior to initiation of nivolumab.    
 
Part B 
1. Meet eligibility for Part A with exception that prior anti-
PD1 therapy (must be with nivolumab in Part A of this 
study) is allowed 
2. No grade 3 IrAE on nivolumab (excluding endocrine 
toxicity managed with replacement therapy) 
3. Tumor biopsy prior to combination treatment is mandatory. 
If a biopsy/resection of a new lesion or primary tumor and 
slow freezing of fresh tissue for single cell RNAseq study 
(as specified in the CLM) is not feasible, the subject is not 
eligible for the study. All biopsies must be core needle or 
excisional. Fine needle aspirate is not acceptable.  
 
Exclusion 
1. Untreated brain metastases 
2. Major surgery or radiation therapy within 14 days of 
starting study treatment 
3. Subjects with active autoimmune disease (see protocol for 
exceptions) 
4. Concurrent medical condition requiring use of systemic 
corticosteroids with prednisone >10 mg per day. 
5.   Prior systemic therapy for Stage IV RCC (except for 
nivolumab as part of part A of this protocol).  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 8 of 71 
STATISTICAL 
CONSIDER 
ATIONS 
 
The primary focus of this trial will be in the evaluation of PD-L1 to 
predict outcome and, also, secondarily to use the PRP model as a 
basis for outcome prediction. We expect that about 45% (or 54 
expected) patients will have 0% PD-L1 and roughly 15% (or 18 
expected) patients will express PD-L1 > 20%, which, given the 
sample size of 120 ccRCC patients provides 90% power using a 
0.05 level two-sided test to test the hypothesis that PD-L1 >20% 
will be associated with significantly improved 1-year PFS rate for 
patients treated with PD-1 blockade (55% vs 13% taken as a 
binomial quantity). Considering the four groups of PD-L1 
expression (0%, 1-5%, 5-20%, >20%), and with an expected patient 
allocation within groups of (45%, 25%, 15%, 15%), the Cochran-
Armitage test gives at least 90% power to detect a trend in 1-year 
PFS of (13%, 19%, 35%, 55%) using a two-sided 0.05 level test for 
trend. Modest changes in the proportions of patients in the various 
PD-L1 categories will not substantially affect the power. For 
example, if the distribution across PD-L1 categories is [25%, 25%, 
25%, 25%] rather than the anticipated [45%, 25%, 15%, 15%] the 
power for the trend test remains greater than 90%. 
 
As a secondary objective, we will apply the PRP model, developed 
in the DF/HCC Kidney SPORE Project 4, to assign each patient a 
probability of having PFS > 1 year.  This will be assessed by both 
RECIST and irRECIST. The validity of the model will be assessed 
by the Brier score as well as via evaluation of the AUC.  The exact 
distribution is unknown, but assuming an overall 1-year PFS of 
28% and that 40% of patients are expected to be “positive” by the 
PRP model, 120 ccRCC patients give 90% power to detect a 29% 
higher 1-year PFS between 48 positive patients and 72 negative 
patients (via Fisher’s exact test and assuming a difference in PFS of 
46% vs 17%). All testing above will be done at 1-sided α = 0.025. 
The specific distributional breakdowns are unknown but the power 
is relatively robust. For example, if the split between positive and 
negative is more even (50/50) then power for the above difference 
in 1-yr PFS remains over 90%. If the actual difference in 1-yr PFS 
is smaller than anticipated for example 25% (44% vs 19%) then the 
test will still have at least 80% power. 
 
At this time, 10 fresh frozen baseline tumor specimens and 3 pairs 
of specimens have been collected with an additional patient likely 
to be collected before accrual of the original 120 patients is 
complete. Therefore, fourteen additional patients are to be enrolled 
to collect fresh frozen specimens necessary to provide 25 baseline 
and 15 paired baseline and resistant fresh frozen samples to be used 
for single cell RNAseq experiments aimed at identifying factors 
associated to resistance as outlined in the DOD Translational 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 9 of 71 
Research Partnership grant to Drs. Atkins and Wu. Assuming 15 
patients non-responsive to nivolumab and up to 10 patients 
responding, comparisons of any quantitative expression level using 
a 0.05 level two-sided two-group t-test will have 80% power to 
detect at least a 1.2 SD shift in means using baseline samples. With 
15 paired samples at baseline and at confirmed radiologic 
progression among the non-responders, there is at least 80% power 
to detect a change in expression of 0.78 SD in any markers using a 
two-sided 0.05 level paired t-test. For two binary markers that are 
at least 50% discordant there is at least 80% power to detect a +/- 
versus -/+ discordance of at least 47% using a two-sided 0.05 level 
McNemar’s test. 
 
Non-clear cell (ncc) RCC patients (comprising a heterogeneous 
group of histologies) will also be enrolled in the trial, at an accrual 
rate that is expected to be 33% that of clear cell patients. Therefore, 
an expected cohort of 40 nccRCC patients will be enrolled in the 
trial and analyzed separately for evidence of anti-tumor activity, 
principally focusing on overall response rate (CR or PR). With 40 
patients, the 95% confidence interval on the true objective response 
proportion will be no wider than 32.4 percentage points and the 
probability of observing five or more responses under the 
hypothesis that the true response rate is 0.20 is at least 92%, hence 
there is high power to detect responses in this cohort should the true 
response rate be interesting. Other endpoints of interest in this 
group of patients will include rates of SD and PFS at 1-year. 
 
Clear cell patients who reach best response of SD at 48 weeks or 
who experience progression will be offered the opportunity to 
enroll in the second component of the study, Part B, continued 
treatment with the addition of ipilimumab. The primary endpoint of 
this portion of the trial will be objective response (CR or PR) taking 
as baseline tumor measurements at the patient’s start of Part B. It is 
expected that roughly one-half of the Part A patients will be 
eligible for and choose to enroll in Part B, or roughly 60 total 
patients. A two-stage design will be used for this portion of the 
study where in the first cohort 29 patients will be accrued, treated 
and evaluated for response in order to provide guidance on whether 
to continue to enroll the entire cohort of 60 patients. The first stage 
analysis will be conducted without pausing accrual to Part B. If 
among the first 29 Part B patients there are at least 2 responses, 
there will be sufficient evidence to continue recruitment to Part B. 
With a true uninteresting response rate of 5%, there is a 57% 
chance of declaring the regimen uninteresting; however, with an 
interesting response rate of 20%, there is greater than 95% chance 
of continuing. If after enrollment of 60 patients there are at least 11 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 10 of 71 
total responses, the lower limit on the 90% confidence interval for 
the true response rate will exclude 10% (ie, the 95% confidence 
interval will range from 10.6% to 28.5%, adjusted for the two-stage 
design). With 18 total responses, the 90% confidence interval on 
the true objective response proportion will exclude 20% (it, the 
confidence interval will range from 20.4% to 41.2%, adjusted for 
the two-stage design).  
 
Ncc RCC patients will also be available to enroll in Part B of the 
study.  An estimated 20 patients will be enrolled and response rates 
in this resistant population will be reported.  If no responses are 
seen in the first 14 patients that response rate will be deemed 
uninteresting. If any confirmed responses are seen, accrual of 
nccRCC patients will continue for all eligible patients completing 
Part A.    
ACCRUAL 
GOALS 
With multicenter accrual of 6-7 patients per month, the study 
should accrue 134 ccRCC patients (original 120 plus an 
additional 14 to provide paired baseline and resistant samples) 
to Part A in 2 years with an additional 1 year of follow-up time 
for Part A (1.5 years for Part B).  
 
The cohort of 40 nccRCC patients will be enrolled and analyzed 
separately for evidence of anti-tumor activity (CR, PR and SD 
and PFS at 1 year of nivolumab). These patients will also be 
eligible for participation in Part B.  We anticipate that the 
accrual of these 40 patients will be able to be completed within 
the 1.5 years needed for accrual of the ccRCC patients. 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 11 of 71 
TABLE OF CONTENTS 
 
Schema ............................................................................................................................. 12 
1. 
Background and Rationale ................................................................................... 13 
2. 
Study Objectives and Endpoints........................................................................... 21 
3. 
Eligibility Criteria .................................................................................................. 22 
4. 
Subject Registration............................................................................................... 25 
5. 
Treatment Plan....................................................................................................... 26  
6. 
Toxicities and Dose Delays .................................................................................... 29 
7. 
Study Calendar & Evaluations ............................................................................. 34 
8. 
Biospecimen Studies and Procedures ................................................................... 37 
9. 
Criteria for Disease Evaluation ............................................................................ 39 
10. Drug Information ................................................................................................... 45 
11. Adverse Events ....................................................................................................... 50 
12. Statistical Methods ................................................................................................. 53 
13. Trial Management ................................................................................................. 57 
14. Data Handling and Record Keeping .................................................................... 58 
15 
Ethics ....................................................................................................................... 59 
16 
References ............................................................................................................... 60 
17. Appendix A ............................................................................................................. 64 
 
 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 12 of 71 
SCHEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR or CR → PART A  
Continue Nivolumab 360 mg IV  
every 3 weeks for 4 doses (12 weeks) then 
Nivolumab 480 mg IV every 4 weeks until 
PD, toxicity or completion of 72 weeks of 
study treatment. Total = 96 weeks 
PD or SD @ 48 weeks → PART B 
Re-induce with Nivolumab 3mg/kg and 
Ipilimumab 1 mg/kg every 3 weeks x 4 doses 
(must complete by week 16)  
Metastatic RCC 
Treatment Naïve 
134 ccRCC 
40 nccRCC 
Screen for Eligibility 
Nivolumab 240 mg IV every 2 weeks x 6 doses (12 weeks) then initial disease assessment  
Toxicity that requires discontinuation of 
study drug or CR/PR or SD 
Continue Nivolumab with a total of  
60 weeks of treatment completed 
continue being followed per protocol 
PD 
Discontinue 
nivolumab  
per Part A and 
evaluate subject 
for Part B 
Tumor Assessments weeks 12, 18 and 24 then every 12 weeks on both Part A and Part B.    
Baseline reset for Part B.  
 
Archival tumor tissue as described in eligibility and Section 8 is required if available prior to treatment 
on Part A.  A fresh biopsy is required after the patient signs consent. Tumor tissue should be slow 
frozen for single cell RNAseq as described in the CLM.  Such biopsy collection and processing is 
required for protocol eligibility for patients 121-134 with ccRCC accrued to this study. Tumor Biopsy 
required at crossover to Part B with slow frozen tissue processing for scRNAseq  
Toxicity that 
requires 
discontinuation of 
study drug or 
CR/PR with a 
total of  
96 weeks of 
treatment 
completed 
continue being 
followed per 
protocol 
Nivolumab 360 mg every 3weeks  
starting week 13-19 for 4 doses (12 weeks) 
then Nivolumab 480 mg IV every 4 weeks 
until PD, toxicity or completion of 48 weeks. 
Total = 60 weeks 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 13 of 71 
1. 
BACKGROUND AND RATIONALE 
 
1.1 
Renal Cancer 
The global incidence of RCC exceeds 300,000 worldwide with nearly 150,000 deaths annually 
with worsening mortality trends in the developing world compared to advanced countries in 
Europe and the United States.[1] In the US, the American Cancer Society’s most recent estimates 
for kidney cancer for 2016 include approximately 62,700 new cases (39,650 in men and 23,050 
in women) and about 14,240 deaths (9,240 men and 5,000 women) from the disease [2]. In the 
US, RCC is the 10th most common cancer with a 1.6% (1 in 63) lifetime risk of developing the 
disease. Metastatic disease is the proximate cause of death for most patients and can present 
equally as either de novo advanced RCC or as relapse following surgery for early stage disease. 
Decrements in life expectancy due to RCC have been estimated to be about 15 years for patients 
in several Western countries and there is a substantial health related quality of life impact [3]. 
Kidney cancer has a propensity to hematogeneously metastasize to any possible location, 
propagate tumor thrombus through the inferior vena cava into the heart, and due to the 
hypervascularity of the tumor is susceptible to tumor hemorrhage, causing additional morbidity 
and extended hospitalizations for management.  Several distinct subtypes of RCC have been 
identified, including: clear cell cancer, comprising the majority of tumors and papillary, 
chromophobe collecting duct and unclassified tumors representing 15-25% of all tumors.  
 
1.1.1 Clear Cell Renal Cell Carcinoma 
Clear cell renal cell carcinomas (ccRCC) represent 75-85% of all RCC.  They typically arise 
from the proximal renal tubule. Macroscopically, they may be solid or less commonly, cystic. In 
addition to occurring sporadically, ccRCC is specifically associated with von Hippel-Lindau 
(VHL) disease (a tumor suppressor gene). Both sporadic and VHL associated RCC typically 
have a deletion in 3p the site of the VHL gene [4] which leads to upregulation of hypoxia-
inducible factor (HIF), even in the absence of hypoxia and promotes VEGF related tumor 
angiogenesis. A poor prognosis is associated with higher nuclear grade or the presence of a 
sarcomatoid pattern.[5] 
 
1.1.2 Non Clear Cell  
Papillary RCC accounts for approximately 15% of all kidney cancers, and these can be divided 
into type 1 and type 2 lesions based upon histopathologic features. Type 1 and type 2 papillary 
carcinomas differ in both clinical features and in their underlying genetic abnormalities. As with 
ccRCCs, papillary RCC originates from the proximal tubule, but these tumors are 
morphologically and genetically distinct malignancies. Type 1 papillary RCC typically presents 
with stage I or II disease, and these patients have a relatively favorable prognosis.  Although type 
1 lesions occur in patients with hereditary papillary RCC, the majority of these are sporadic. In 
the hereditary form of this disease, activating germline mutations are seen in MET. In 
nonhereditary forms of the disease, somatic mutations in MET have been identified in 
approximately 10 to 20 percent of cases [6]. In total, altered MET status (defined as mutation, 
splice variant, or gene fusion) or increased chromosome 7 copy number (which encodes MET 
but may also involve other genes) was identified in 81% of type 1 papillary renal-cell carcinoma.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 14 of 71 
Type 2 papillary RCC is frequently associated with aggressive tumors that are stage III or IV at 
presentation and are associated with a poor prognosis. These tumors have also been seen in the 
hereditary leiomyomatosis and renal cell cancer syndrome, which is caused by germline 
mutation in the gene for fumarate hydratase (FH). Very few patients had alterations in the MET 
pathway. 
 
Chromophobe carcinomas make up approximately 5% of all RCCs.  Histologically, they are 
composed of sheets of cells that are darker than ccRCC (Thoenes). They lack the abundant lipid 
and glycogen that is characteristic of most RCCs, and originate from the intercalated cells of the 
collecting system. Chromophobe carcinomas may have a lower risk of disease progression and 
death compared with ccRCC which likely relates to both their presentation at earlier stage and 
overall slower growth rate.  
 
1.2 
Renal Cancer Therapy 
First-line treatment for clear cell RCC typically involves vascular endothelial growth factor 
receptor (VEGFR) tyrosine kinase inhibitors (TKIs) sunitinib or pazopanib. Additional agents for 
second-line therapy have included alternative VEGFR TKIs (e.g. axitinib) the mTOR inhibitor 
everolimus. as well as agents active against multiple tyrosine kinases. Recently both nivolumab 
an anti- programmed death-1 (PD1) based immunotherapy (see below) and cabozantinib a TKI 
targeting both VEGFR and Met, have shown overall survival (OS) benefits relative to mTOR 
inhibition in patients with prior VEGRF TKI therapy resulting in their FDA approval. 
 
1.3 
Nivolumab +/- Ipilimumab Summary 
Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody 
(HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) 
cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative 
regulatory molecule expressed by activated T and B lymphocytes [7]. Binding of PD-1 to its 
ligands, programmed death–ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of 
lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes 
immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-
antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using 
standard mammalian cell cultivation and chromatographic purification technologies. The clinical 
study product is a sterile solution for parenteral administration.  OPDIVO (nivolumab) is 
approved for use in multiple countries including the United States (US, Dec-2014), the European 
Union (EU, Jun-2015), and Japan (Jul-2014). 
 
1.3.1 Non-Clinical Studies  
Nivolumab has been shown to bind specifically to the human PD-1 receptor and not to related 
members of the CD28 family [8, 9]. Nivolumab inhibits the interaction of PD-1 with its ligands, 
PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) 
release in vitro [9-11]. Nivolumab binds with high affinity to activated human T-cells expressing 
cell surface PD-1 and to cynomolgus monkey PD-1.  In a mixed lymphocyte reaction (MLR), 
nivolumab promoted a reproducible concentration-dependent enhancement of IFN- γ release [12] 
In intravenous (IV) repeat-dose toxicology studies in cynomolgus monkeys, nivolumab was well 
tolerated at doses up to 50 mg/kg, administered weekly for 5 weeks, and at doses up to 50 mg/kg, 
administered twice weekly for 27 doses. While nivolumab alone was well tolerated in 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 15 of 71 
cynomolgus monkeys, combination studies have highlighted the potential for enhanced toxicity 
when combined with other immunostimulatory agents [13]. In addition, an enhanced pre- and 
postnatal development (ePPND) study in pregnant cynomolgus monkeys with nivolumab was 
conducted [14]. Administration of nivolumab at up to 50 mg/kg 2QW was well tolerated by 
pregnant monkeys; however, nivolumab was determined to be a selective developmental toxicant 
when administered from the period of organogenesis to parturition at > 10 mg/kg). Specifically, 
increased developmental mortality (including late gestational fetal losses and extreme 
prematurity with associated neonatal mortality) was noted in the absence of overt maternal 
toxicity. There were no nivolumab-related changes in surviving infants tested throughout the 6-
month postnatal period. Although the cause of these pregnancy failures was undetermined, 
nivolumab-related effects on pregnancy maintenance are consistent with the established role of 
PD-L1 in maintaining fetomaternal tolerance in mice [15]. 
 
1.3.2 Effects in Humans 
The PK, clinical activity, and safety of nivolumab have been assessed in subjects with non-small 
cell lung cancer (NSCLC), melanoma, and ccRCC in addition to other tumor types. Nivolumab 
is being investigated both as monotherapy and in combination with chemotherapy, targeted 
therapies, and other immunotherapies. Nivolumab is approved in multiple countries including the 
US for treatment of previously treated, unresectable or metastatic melanoma and previously 
treated, metastatic squamous NSCLC, the EU for treatment of previously treated, unresectable or 
metastatic melanoma, and Japan for treatment of unresectable melanoma. 
 
1.3.2.1  
Clinical Pharmacokinetics 
The pharmacokinetics (PK) of nivolumab was studied in subjects over a dose range of 0.1 to 10 
mg/kg administered as a single dose or as multiple doses of nivolumab every 2 or 3 weeks. The 
geometric mean (% CV%) clearance (CL) was 9.5 mL/h (49.7%), geometric mean volume of 
distribution at steady state (Vss) was 8.0 L (30.4%), and geometric mean elimination half-life 
(t1/2) was 26.7 days (101%). Steady-state concentrations of nivolumab were reached by 12 
weeks when administered at 3 mg/kg Q2W, and systemic accumulation was approximately 3-
fold. The exposure to nivolumab increased dose proportionally over the dose range of 0.1 to 10 
mg/kg administered every 2 weeks. The clearance of nivolumab increased with increasing body 
weight. A PK analysis suggested that the following factors had no clinically important effect on 
the CL of nivolumab: age (29 to 87 years), gender, race, baseline LDH, PD-L1. A PK analysis 
suggested no difference in CL of nivolumab based on age, gender, race, tumor type, baseline 
tumor size, and hepatic impairment. Although ECOG status, baseline glomerular filtration rate 
(GFR), albumin, body weight, and mild hepatic impairment had an effect on nivolumab CL, the 
effect was not clinically meaningful. When nivolumab is administered in combination with 
ipilimumab, the CL of nivolumab was increased by 24%, whereas there was no effect on the 
clearance of ipilimumab. Additionally, PK and exposure response analyses have been performed 
to support use of 240 mg Q2W dosing as a substitute for the previously studied 3 mg/kg Q2W 
regimen. Using a PK model, exposure of nivolumab at 240 mg flat dose was identical to a dose 
of 3 mg/kg for subjects weighing 80 kg, which was the approximate median body weight in 
nivolumab clinical trials. The 240 mg q 2 week flat dose of nivolumab monotherapy has recently 
received FDA approval.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 16 of 71 
1.3.2.2 
Clinical Efficacy 
Nivolumab has demonstrated durable responses exceeding 6 months as monotherapy and in 
combination with ipilimumab in several tumor types, including NSCLC, melanoma, RCC, and 
some lymphomas. In confirmatory trials, nivolumab as monotherapy demonstrated a statistically 
significant improvement in OS as compared with the current standard of care in subjects with 
advanced or metastatic NSCLC and in subjects with unresectable or metastatic melanoma. 
Nivolumab in combination with ipilimumab improved PFS and ORR over ipilimumab alone in 
subjects with unresectable or metastatic melanoma.  
 
1.3.2.3 
Clinical Safety 
The overall safety experience with nivolumab, as a monotherapy or in combination with other 
therapeutics, is based on experience in approximately 8,600 subjects treated to date. For 
monotherapy, the safety profile is similar across tumor types. There is no pattern in the 
incidence, severity, or causality of AEs to nivolumab dose level. In Phase 3 controlled studies, 
the safety profile of nivolumab monotherapy is acceptable in the context of the observed clinical 
efficacy, and manageable using established safety guidelines. Clinically relevant AEs typical of 
stimulation of the immune system were infrequent and manageable by delaying or stopping 
nivolumab treatment and timely immunosuppressive therapy or other supportive care. In several 
ongoing clinical trials, the safety of nivolumab in combination with other therapeutics such as 
ipilimumab, cytotoxic chemotherapy, anti-angiogenics, and targeted therapies is being explored. 
Most studies are ongoing and, as such, the safety profile of nivolumab combinations continues to 
evolve. The most advanced combination under development is nivolumab + ipilimumab in 
subjects with unresectable or metastatic melanoma. Results to date suggest that the safety profile 
of nivolumab + ipilimumab combination therapy is consistent with the mechanisms of action of 
nivolumab and ipilimumab. The nature of the AEs is similar to that observed with either agent 
used as monotherapy; however, both frequency and severity of most AEs are increased with the 
combination. 
 
1.4 
Nivolumab in RCC 
A first-in-human Phase I study of nivolumab was performed in patients with treatment refractory 
solid tumors [16]. Nivolumab was administered as a single dose ranging from 0.3 to 10mg/kg 
and objective responses were noted including in a patient with RCC and there were no dose 
limiting toxicities observed within 4 weeks of the initial dose. The serum half-life of nivolumab 
ranged from 12 to 20 days. A multi-dose Phase I dose escalation trial extended the above 
findings in 296 patients with advanced solid tumors given nivolumab at doses from 0.1 to 10 
mg/kg every 2 weeks for up to 2 years [17].  Objective tumor responses were noted in 9 of 33 
patients with RCC. Common treatment related side effects were fatigue, anorexia, nausea, rash, 
and diarrhea. Grade 3 or 4 toxicities were reported in 14% of patients and evident at all dose 
levels without obvious dose dependency but only 15 patients (5%) discontinued treatment for 
toxicity reasons. Immune related adverse events of special interest were observed including 
pneumonitis, colitis, hepatitis, hypophysitis and thyroiditis but were reversible. Extended follow 
up of patients on this study showed a median response duration of 12.9 months and median 
overall survival in this heavily pretreated population was 22.4 months [18]. Three of 5 patients 
who stopped treatment while responding continued to respond for at least 45 weeks. Among 168 
RCC patients randomized in blinded fashion to nivolumab dosed at 0.3, 2 and 10mg/kg, there 
was no observable dose-response relationship with objective responses in 20-22% of patients and 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 17 of 71 
median survival ranging from 18.2 to 25.5 months [19]. In the Checkmate 025 Phase III trial, 
821 patients with advanced RCC with a clear cell component who had received previous 
antiangiogenic therapy, were randomly assigned to receive 3 mg/kg of nivolumab every 2 weeks 
or everolimus [19, 20]. The primary outcome, overall survival was significantly improved for 
nivolumab (median 25.0 versus 19.6 months) with HR 0.73 (98.5% CI, 0.57 to 0.93; P=0.002).  
The objective response rate was higher with nivolumab (25% vs. 5%; P<0.001) but the median 
progression-free survival was similar at 4.6 months versus 4.4 months. Grade 3 or 4 treatment-
related adverse events were lower at 19% for nivolumab versus 37% for everolimus. Quality of 
life improved significantly more in the nivolumab group over 2 years relative to the everolimus 
group. These results led to the approval of nivolumab as second line therapy for patients with 
advanced RCC in the US. The absence of improvement in PFS with nivolumab suggested that 
many patients did not have benefit from nivolumab, highlighting the importance of predictive 
biomarker research.  
 
In a biomarker-based trial of 91 patients with advanced RCC, 67 pretreated patients were 
randomized to receive 0.3, 2 or 10mg/kg of nivolumab every 3 weeks and 24 treatment-naïve 
patients received the 10mg/kg dose [21]. The primary objective was to study the 
immunomodulatory activity of nivolumab on tumor biopsies and serum chemokines. Among 56 
evaluable specimens, 18 (32%) were PD-L1 positive defined as > 5% tumor cells with any tumor 
membrane staining by the Dako assay. Four of 18 (22%) of PD-L1(+) and 3/38 (8%) PD-L1(-) 
patients had objective responses and the overall response rate in the entire cohort was 16% with 
expected grade 3 immune related adverse events in 15%. 
 
1.5 
Nivolumab + Ipilimumab in RCC 
The combination of nivolumab and ipilimumab has been extensively tested in patients with 
metastatic melanoma and found to have superior clinical outcomes to ipilumumab and likely 
nivolumab alone but at the cost of a higher frequency of serious adverse events [22, 23]. In a 
Phase I trial (CheckMate 016) patients with advanced RCC were randomized to receive 
nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3 + I1, 47 patients) or nivolumab 1 mg/kg plus 
ipilimumab 3 mg/kg (N1 + I3, 47 patients) intravenously every 3 weeks for 4 doses followed by 
nivolumab every 2 weeks [24]. An exploratory nivolumab 3 mg/kg plus ipilimumab 3 mg/kg arm 
(N3 + I3) showed unacceptable early toxicity after 6 patients and did not proceed to the 
expansion phase. Approximately half the patients were previously treated. Treatment-related 
toxicities were seen in 88% of patients and 16% discontinued therapy for toxicity reasons. 
Serious Grade 3 or 4 treatment-related adverse events occurred in 34% and 64% of patients in 
N3 + I1 and N1 + I3, respectively, most commonly manifest as elevated lipase or amylase, 
elevated liver function tests, diarrhea and colitis. After a median 8 months of follow up, the 
objective response rate was 38% and 43% and median progression free survival was 30.3 and 36 
weeks respectively in N3 + I1 and N1 + I3 arms. Among responders, the median duration of 
response was 67.7 weeks (range 4.1+ to 91.1+) in the N3 + I1 arm and 81.1 weeks (range 6.1+ to 
81.1+) in the N1 + I3 arm. Overall both treatment arms appeared to confer similar anti-tumor 
activity but the N1 + I3 arm was associated with higher gastrointestinal and hepatic toxicities. 
The promising activity and tolerability of the N3 + I1 schedule has led to an ongoing randomized 
Phase III registrational trial comparing this combination to sunitinib monotherapy in the 
approved schedule, in patients with advanced clear cell RCC.  This trial reached its accrual goal 
of 1070 patients in the fall of 2015. The co-primary endpoints are progression free and overall 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 18 of 71 
survival.  Trial results were reported in 2017 and published in 2018 [25]. The combination of 
nivolumab with ipilimumab improved PFS, ORR and OS over sunitnib in patients with 
intermediate and poor risk treatment naïve RCC and was FDA approved in April of 2018 for 
these patients.  The nivo/ipi combination also prolonged OS relative to sunitinib when the good 
risk group was included in the analysis.  The treatment was reasonably well tolerated with only a 
3rd of patients having grade 3 IrAes and Quality of Life analyses showed the combination to be 
superior to sunitinib [25].  
 
1.6 
Biomarkers for Response and Resistance to Anti-PD1 Based Immunotherapy 
Several prognostic clinical factors and models (e.g. MSKCC, Heng) have been developed to risk 
stratify survival outcomes for patients with advanced RCC. However, predictive biomarker 
development is critical to identify patient subgroups who are likely to experience frequent and/or 
durable responses to particular therapies. The importance of this unmet need is heightened by the 
expense, prolonged duration of exposure to, or toxicities of current therapeutic agents. Tumor 
associated PD-L1 expression has been proposed as a potential biomarker for sensitivity to PD-1 
pathway inhibitors in other tumors.  
 
In the phase I trial of nivolumab in patients with advanced solid tumors, 9 of 25 patients with 
PD-L1 positive tumors responded compared with 0 of 17 patients with PD-L1 negative tumors 
(p=0.006); only 5 of these patients had mRCC.[17] In the Checkmate 025 registration Phase III 
trial of nivolumab versus everolimus, tumor PD-L1 membrane expression (≥1% vs. <1% and 
≥5% vs. <5%) was evaluated centrally using the Dako PD-L1 immunohistochemical stain [20]. 
Among 756 patients with quantifiable PD-L1 expression, 181 (24%) had > 1% PD-L1 
expression in at least 100 tumor cells. However, the benefit of nivolumab relative to everolimus 
on overall survival did not differ in these two PDL1 defined subgroups at either this cutoff or 
when a 5% cut off was used. Interestingly, patients bearing PD-L1 positive tumors appeared to 
have shorter overall survival on either treatment relative to those with PD-L1 negative tumors, 
consistent with previous reports of PD-L1 expression being a marker of poor prognosis.  The 
lack of predictive value for PD-L1 expression in RCC diverges from data for nivolumab in lung 
cancer and melanoma. However, it should be noted that those data primarily focused on ORR 
rather than overall survival and ORR data for the Checkmate 025 study has yet to be reported.  In 
the aforementioned Phase I study of atezolizumab in RCC, there was no suggestion of a 
correlation between tumor cell PD-L1 status and antitumor activity. However immune cell PD-
L1 expression measured using a diagnostic Spring Biosciences PD-L1 antibody SP142, 
suggested a trend towards improved ORR, PFS and OS with > 1% immune cell PD-L1 
expression which was observed in 63% of the informative patients.  
 
These data highlight the limitations of using PD-L1 expression to select patients for PD-1 axis 
targeting antibodies. The assays for PD-L1 expression are difficult to standardize, use distinct 
proprietary antibodies that have not been compared with each other, use different cutoff points 
and measure expression on different cells within the tumor microenvironment (tumor cells or an 
aggregate reading of a variety of immune cells). Furthermore, PD-L1 is an inducible molecule 
and tumors are frequently heterogeneous, affecting assay reproducibility especially at the low 
end of the range. Discordance between primary tumor and metastases for PD-L1 positivity in 
both directions was observed in kidney cancer in 11 of 53 cases (20.8%) using a validated anti-
PD-L1 antibody (405.9A11) and formally quantified membranous expression in tumor cells [26].  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 19 of 71 
The predictive utility of PD-L1 expression is likely to be more challenging in combination 
regimens. Lastly, while PD-L1 positivity is associated with poorer survival in non-clear cell 
RCC, its predictive value for immunotherapy is unknown [27].  
 
At this time therefore, PD-L1 assay results are inadequate to be used to select or otherwise 
manage patients with advanced RCC receiving PD-1 targeting agents. Continued prospective 
biomarker validation studies, particularly looking at factors such as CD8 cell infiltrate and IFN-
related gene expression signatures alone or in combination with PD-L1 expression which have 
shown more predictive power in other tumor sets, are clearly necessary in RCC.  
 
1.7 
Rationale for the Current Trial 
Agents that target the VEGF and mTOR pathways significantly prolong progression free and 
likely overall survival for patients with metastatic ccRCC, but resistance invariably develops, 
often within the first year [28]. The clinical experience with high dose (HD) IL-2 has provided 
proof of principle that immunotherapy can produce durable responses in a small percentage of 
patients with ccRCC and obviate the need for subsequent therapy [29]. However, its toxicity and 
limited efficacy has severely narrowed its application. Agents that induce a high proportion of 
durable tumor responses with acceptable toxicity remain a critical unmet need for RCC patients. 
Tumor-induced immune suppression may explain why immunotherapies often fail to 
demonstrate clinical activity. The programmed death-1 (PD-1) pathway is one of the most 
critical mediators of tumor-induced immune suppression [30]. Many human solid tumors, 
including cc and non-ccRCC, express PD-L1, one of the ligands for PD-1, as a consequence of 
oncogene expression or as an adaptive response to exposure from IFN-γ produced by cytotoxic T 
lymphocytes [31]. PD-1 engagement by its ligands (PD-L1, PD-L2) inhibits T-cell proliferation, 
cytokine production, cytolytic function and survival [32]. Tumor-infiltrating lymphocytes (TIL) 
from patients typically express PD-1 and subsequently have impaired anti-tumor functionality 
[33, 34]. PD-L1 expression on renal tumors portends worse prognosis highlighting the clinical 
impact of this interaction [35]. 
 
Ongoing clinical trials evaluating PD-1/PD-L1 antibodies have demonstrated promising clinical 
efficacy with durable benefit in a subset of ccRCC patients who have progressed after prior 
therapy [17, 36-38]. Preliminary correlative studies have demonstrated that while tumor PD-L1 
expression may increase the likelihood of benefit with PD-1 blockade, it fails to identify all 
responders. [17, 37, 39, 40]. Given the robust antitumor activity of VEGF pathway inhibitors, the 
application of single agent PD-1 blockade in the treatment naïve setting will require the 
development of biomarkers with greater positive predictive value. Combination approaches are 
actively being investigated (e.g. combined inhibition of both CTLA-4 and PD-1 and need to be 
rationally designed and implemented, given their additive toxicity and cost. In particular, tumors 
may escape PD-1 or PD-L1 blockade due to suboptimal T-cell activation, and CTLA-4 blockade 
could potentially overcome this escape mechanism [41]. Prior to PD-1 or PD-L1 blockade, 
CTLA-4 blockade could facilitate naïve T-cell activation and boost tumor reactive T-cells, 
producing interferon and resulting in upregulation of PD-L1 expression in the tumor 
microenvironment [42]. When used after PD-1 or PD-L1 blockade, CTLA-4 blockade could 
deplete T-regulatory cells that impair CD8-positive T-cell function [43]. Further work is needed 
to investigate the hypothesis that patients who do not respond to PD-1 or PD-L1 blockade may 
be salvaged by the addition of CTLA-4 blockade. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 20 of 71 
To optimize the therapeutic potential of single agent, PD-1 blockade in patients with kidney 
cancer, we propose a translational clinical trial that integrates clinicopathologic assessment, 
genomics and immunology to gain clearer mechanistic understanding of the effects of PD-1 
blockade.  
 
Our goals are to address several critical unanswered questions including: 1) How active is PD-1 
blockade in treatment naïve kidney cancer? 2) What factors, in addition to PD-L1 expression, 
can reliably predict durable response? 3) Do gene expression signatures which are likely 
capturing the presence, magnitude, and activity of adaptive immune infiltrates reliably predict 
durable response 4) Is there a threshold for PD-L1 expression in either the tumor or immune cell 
infiltrate that accurately predicts durable response? 5) Is PD-L1 expression uniform and stable in 
an individual tumor and between a primary tumor and its metastases? 6) What are the 
mechanisms of innate resistance to PD-1 pathway blockade?  7) Can the addition of ipilimumab 
overcome resistance and/or enhance response it patients with prolonged stable disease?  
 
Both the PD-1 blocking antibody nivolumab and PD-L1 blocking antibody atezolizumab are well 
tolerated and have shown efficacy in mRCC as monotherapy [34]. Nivolumab is a high affinity 
humanized monoclonal IgG4 antibody directed against human PD-1. It blocks its interaction 
with its ligands PD-L1 and PD-L2.  It has shown encouraging efficacy in patients with 
melanoma and lung cancer [44, 45] and is currently FDA approved for patients with VEGFR 
TKI resistant RCC.   The application of PD-1 pathway blockade in the treatment naïve setting 
may yield even better results and delay the need for subsequent lines of therapy in selected 
patients.  Patients with melanoma who were previously untreated had greater response rates to 
nivolumab than ipilimumab-treated patients (40% vs 28% respectively).  While combination 
therapies will likely play a large role in the future for many patients, there is a distinct subset of 
patients with RCC that will likely benefit with durable responses and increased PFS rate at 1 year 
to single immune checkpoint blockade [24, 37, 38, 46]. This hypothesis will be explored in Part 
A. The ability of the addition of ipilimumab to overcome resistance or improve response in 
patients following nivolumab will be explored in Part B.  
 
Approximately 20% of all patients with kidney cancer have nccRCC. A recent analysis of tumor 
specimens revealed that while nccRCC expresses less PD-L1 on average, a substantial portion of 
nccRCC tumors express >5% PD-L1 on their surface, including: 43% of translocation-positive 
(3/7), 50% of oncocytoma (2/4), and 10% of papillary RCC (5/50) [47]. In the Phase 1 trial of 
atezolizumab, 1/7 non-clear cell mRCC patients had a partial response to therapy [37]. Given the 
current lack of effective therapies for sarcomatoid and non-clear cell kidney cancer and the 
preliminary evidence of clinical activity, the exploration of PD-1 blockade seems rational in this 
substantial group of patients.  
 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 21 of 71 
2. 
STUDY OBJECTIVES AND ENDPOINTS 
 
2.1 
Objectives 
 
2.1.1 Primary Objective 
Determine the PFS rate at 1 year of nivolumab in patients with treatment naïve ccRCC based on 
tumor PD-L1 expression. 
 
2.1.2 Secondary Objectives 
 Determine the PFS rate at 1 year- by both RECIST and irRECIST of nivolumab in 
patients with treatment naïve ccRCC based on the PD1- Blockade Durable Response 
Predictive (PRP) biomarker model developed in the DFHCC Kidney Cancer SPORE 
 Determine the objective response rate (CR/PR=ORR), the ORR based on PDL1 
expression and the PRP model, and duration of response for nivolumab in patients with 
treatment naïve ccRCC 
 Determine the response rate of combined nivolumab and ipilimumab therapy at the time 
of nivolumab failure (or lack of response at 1 year) 
 Determine the clinical activity (CR, PR and SD) and PFS at 1 year of nivolumab in 
patients with treatment naive nccRCC 
 Assess the toxicity of nivolumab monotherapy in patients with treatment naïve cc or 
nccRCC 
 
2.1.3 Correlative/Exploratory Objectives 
 Explore novel potential predictive biomarkers for patients with treatment naïve ccRCC 
and nccRCC 
 Explore the mechanisms of innate and acquired resistance to nivolumab therapy in 
treatment naïve patients with ccRCC 
 Identify biomarkers associated with response to nivolumab + ipilimumab in patients 
whose disease has not responded or progressed on nivolumab monotherapy 
 
2.2 
Endpoints 
 
2.2.1 Primary Endpoint 
 PFS is defined as the time from Day 1 of treatment until the criteria for disease 
progression is met as defined by RECIST 1.1 or death as a result of any cause.  
 The primary focus of this trial will be in the evaluation of PD-L1 expression levels to 
predict outcome. We expect that about 45% (or 54 expected) patients will have 0% PD-
L1 and roughly 15% (or 18 expected) patients will express PD-L1 > 20%, which, given 
the sample size of 120 ccRCC patients provides 90% power using a 0.05 level two-sided 
test to test the hypothesis that PD-L1 >20% will be associated with significantly 
improved 1-year PFS rate for patients treated with PD-1 blockade (55% vs 13% taken as 
a binomial quantity).  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 22 of 71 
2.2.2 Secondary Endpoints 
 Apply the PRP model, developed in the DF/HCC Kidney SPORE Project 4, to assign 
each patient a probability of having PFS > 1 year. 
 The endpoint for Part B (addition of ipilimumab) will be objective response (CR or PR) 
taking as baseline tumor measurements at the patient’s start of Part B. 
 An expected cohort of 40 nccRCC patients will be enrolled in the trial and analyzed 
separately for evidence of anti-tumor activity, principally focusing on objective response 
rate (CR or PR). 
 Toxicity by CTCAE criteria of nivolumab monotherapy in treatment naïve patients with 
cc and nccRCC.  
 
2.2.3 Correlative Endpoint 
 Additional correlative studies will be performed in order to identify predictors of 
response and resistance.  
 
3. 
ELIGIBILITY CRITERIA 
 
3.1 
Inclusion Criteria-Part A 
Subject must meet all of the following applicable inclusion criteria to participate in this study: 
 
1. Patients must have histologically confirmed advanced RCC (any histology).  Collecting duct 
tumors and tumors originating from the renal pelvis or upper urinary tract are considered of 
urothelial origin and are excluded from this protocol.   
 
2. Patients must have at least one measurable site of disease, per RECIST 1.1, that has not been 
previously irradiated. If the patient has had previous radiation to the marker lesion(s), there 
must be evidence of progression since the radiation. 
 
3. Archival tissue of a metastatic lesion obtained within 1 year prior to study registration 
(within 4 weeks preferred) and tumor tissue from nephrectomy is required if available.  In 
addition to archival tissue of a metastatic lesion and nephrectomy, patients must have at least 
one site of disease (not including bone metastases) accessible for biopsy.  If biopsy/resection 
of a new lesion or primary tumor and slow freezing of fresh tissue for single cell RNAseq 
study (as specified in the CLM) is not feasible, the subject is not eligible for the study. All 
biopsies must be core needle or excisional. Fine needle aspirate is not acceptable. NOTE: 
The tissue collected from a surgical resection or multiple core biopsies of either a metastatic 
lesion or primary tumor for the slow freezing of fresh tissue after the patient has signed 
consent for the study could also be used for collecting the FFPE specimens. 
 
4. ECOG performance status 0-2. 
 
5. Age ≥ 18 years. 
 
6. Have signed the current approved informed consent form. 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 23 of 71 
7. Patients must have adequate organ function within 14 days prior to study entry as evidenced 
by screening laboratory values that must meet the following criteria:  
 
System 
Laboratory Value 
Hematological 
White blood cell (WBC) 
≥ 2000/µL 
Absolute Neutrophil Count (ANC) 
≥ 1500/μL 
Platelets (Plt) 
≥ 100 x103/μL 
Hemoglobin (Hgb) 
> 9.0 g/dL (with or without transfusion) 
Renal 
Serum Creatinine OR 
≤ 1.5 x ULN; if creatinine > 1.5, subject 
must demonstrate CrCl outlined below. 
Calculated or measured creatinine clearance1 
≥ 40 mL/min using Cockcroft-Gault formula 
Hepatic 
Bilirubin2 
≤ 1.5× upper limit of normal (ULN) 
Aspartate aminotransferase (AST) 
≤ 3 × ULN 
Alanine aminotransferase (ALT) 
≤ 3 × ULN 
1: Female CrCl = (140 - age in years) x weight in kg x 0.85 
                           72 x serum creatinine in mg/dL 
Male CrCl = (140 - age in years) x weight in kg x 1.00  
                            72 x serum creatinine in mg/dL 
2: Except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL 
 
8. Patients should not have received prior systemic therapy for metastatic RCC. Prior 
radiotherapy must have been completed at least 2 weeks prior to the administration of study 
drug.  Patients must be 2 weeks from prior major surgery and 1 week from pre-treatment 
biopsy.  Prior systemic adjuvant therapy (excluding with PD1 or CTLA4 pathway blockers) 
is allowed if treatment completed > 12 months previously.  
 
9. Women of childbearing potential (WOCBP) must use appropriate method(s) of 
contraception. WOCBP should use an adequate method to avoid pregnancy for 5 months 
after the last dose of study drug. NOTE: Contraception is not required for male participants. 
 
10. Women of childbearing potential must have a negative serum or urine pregnancy test 
(minimum sensitivity 25 IU/L or equivalent units of HCG) during screening for registration 
purposes. This pregnancy test should be repeated within 24 hours prior to the start of 
nivolumab. NOTE: “Women of childbearing potential” is defined as any female who has 
experienced menarche and who has not undergone surgical sterilization (hysterectomy or 
bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 
months of amenorrhea in a woman over 45 in the absence of other biological or physiological 
causes. In addition, women under the age of 55 must have a documented serum follicle 
stimulating hormone (FSH) level less than 40 mIU/ml. 
 
11. Women must not be breastfeeding.  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 24 of 71 
12. Be willing and able to comply with this protocol. 
 
3.2 
Exclusion Criteria 
1. Patients are excluded if they have active brain metastases or leptomeningeal metastases. 
Subjects with brain metastases are eligible if metastases have been treated and there is no 
magnetic resonance imaging (MRI) evidence of progression for at least 2 weeks after 
treatment is complete and within 28 days prior to the first dose of nivolumab administration. 
There must also be no requirement for immunosuppressive doses of systemic corticosteroids 
(> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. 
 
2. Patients with controlled brain metastases are allowed on protocol if they had brain metastases 
that were surgically resected without recurrence and/or up to 3 metastases treated with SRS 
without progression on MRI obtained at least 2 weeks after completion of radiation and 
within 28 days prior to initiation of nivolumab.    
 
3. Patients should be excluded if they have an active, known or suspected autoimmune disease. 
Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual 
hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis 
not requiring systemic treatment, or conditions not expected to recur in the absence of an 
external trigger 
 
4. Patients should be excluded if they have a condition requiring systemic treatment with either 
corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive 
medications within 14 days of study drug administration. Inhaled or topical steroids and 
adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence 
of active autoimmune disease. 
 
5. As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab 
combinations, drugs with a predisposition to hepatoxicity should be used with caution in 
patients treated with nivolumab-containing regimen. 
 
6. Active infection requiring systemic therapy  
 
7. Has any other medical or personal condition that, in the opinion of the site investigator, may 
potentially compromise the safety or compliance of the patient, or may preclude the patient’s 
successful completion of the clinical trial.  
 
8. Patients should be excluded if they are positive test for hepatitis B virus surface antigen 
(HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic 
infection 
9. Patients should be excluded if they have known history of testing positive for human 
immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) 
 
10. Allergies and Adverse Drug Reaction 
 History of allergy to study drug components 
 History of severe hypersensitivity reaction to any monoclonal antibody 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 25 of 71 
11. Known additional malignancies within the past 3 years (excluding basal of squamous cell 
skin cancers, CIS or localized prostate cancer that has been treated or is being observed) 
 
12. Prior solid organ or stem cell transplant 
 
3.3 
Inclusion/Exclusion Criteria- Part B 
1. Must meet eligibility criteria for initiation of Part A with the exception of being allowed to 
have prior nivolumab in Part A of this protocol. 
 
2. Must have evidence of either RECIST 1.1 defined Disease Progression or Stable Disease 1 
year after initiating nivolumab therapy 
 
3. Tumor biopsy prior to combination treatment is mandatory. If a biopsy/resection of a new 
lesion or primary tumor and slow freezing of fresh tissue for single cell RNAseq study (as 
specified in the CLM) is not feasible, the subject is not eligible for the study. All biopsies 
must be core needle or excisional. Fine needle aspirate is not acceptable. 
 
4. Must not have had a Grade ≥ 3 irAE on nivolumab monotherapy (excluding endocrine 
toxicity managed with replacement therapy). 
 
5. Must not have untreated brain metastases. 
 
6 Must not have had major surgery or radiation therapy within 14 days of starting study 
treatment. 
 
7. Must not have active autoimmune disease (see protocol for exceptions). 
 
8.  Must not have a concurrent medical condition requiring use of systemic corticosteroids 
with prednisone >10 mg per day. 
 
9. Must not have had prior systemic therapy for Stage IV RCC (except for nivolumab as 
part of part A of this protocol).  
 
 
4. 
SUBJECT REGISTRATION 
All subjects must be registered through HCRN’s electronic data capture (EDC) system. A subject 
is considered registered when an “On Study” date is entered into the EDC system. 
 
Subjects must be registered prior to starting protocol therapy and begin therapy within 5 
business days of registration.  
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 26 of 71 
5. 
TREATMENT PLAN 
We will conduct a prospective Phase II trial of nivolumab in 134 treatment naïve patients with 
ccRCC. Eligible patients with biopsiable (biopsied) disease will receive nivolumab 240 mg IV 
every 2 weeks x 6 doses (2 cycles) then nivolumab every 3 weeks at a dose of 360 mg IV for 4 
doses (2 cycles) followed by nivolumab 480 mg IV every 4 weeks. Tumor response will be 
assessed at weeks 12, 18 and 24 and then every 12 weeks.  For patients who experience RECIST 
1.1 defined PD, but remain clinically stable (and asymptomatic), a confirmatory scan after 4-6 
weeks of additional therapy is suggested. Patients with persistent PD at confirmatory scan will be 
evaluated for enrollment on Part B of this study. Symptomatic patients may be evaluated for Part 
B immediately.  Patients without confirmed PD can continue on nivolumab therapy.   
 
Patients who experience symptomatic or confirmed PD (or have best response of SD at 48 
weeks/end of Cycle 6) on nivolumab monotherapy will be eligible for consideration for Part B. 
Part B involves the addition of ipilimumab for up to 4 doses while maintaining nivolumab 
therapy. Dose of ipilimumab will be 1 mg/kg every 3 weeks together with nivolumab changed to 
3 mg/kg every 3 weeks for up to 4 doses (must complete by week 16 of Part B). Nivolumab will 
revert to 360 mg every 3 weeks after the completion of treatment with ipilimumab for 4 doses (2 
cycles) followed by nivolumab 480 mg IV every 4 weeks (must be started between week 13-19).  
Patients will be followed with serial imaging assessments weeks 12, 18 and 24 and then every 12 
weeks after the initiation of ipilimumab. The tumor measurements at the time of (or within 4 
weeks of) ipilimumab institution will be the new baseline.   
 
Patients for Part B must still meet the eligibility criteria for initial study enrollment.  Patients 
with Grade 3 toxicity on nivolumab monotherapy, serious symptomatic disease that in the 
opinion of the site investigator requires immediate use of an alternative treatment approach or 
continued PR/CR will be excluded from enrolling in Part B.  It is estimated that roughly half of 
the patients accrued to the first-line treatment will go on to enroll in Part B.  
 
An additional biopsy will be performed of a metastatic lesion at time of confirmed PD in all 
patients enrolling in Part B. Confirmation of tumor in the biopsy specimen must occur prior to 
initiation of treatment on Part B.  Subjects unable to undergo a new tumor biopsy and have tissue 
slow frozen for scRNAseq are not eligible for Part B.  
 
An additional cohort of 40 non-ccRCC patients will be enrolled and analyzed separately for 
evidence of anti-tumor activity (CR, PR and SD and PFS at 1 year of nivolumab). These patients 
will also be eligible for participation in Part B (as described for patients with ccRCC).  We 
anticipate that the accrual of these 40 patients will be able to be completed within the 1.5 years 
needed for accrual of the ccRCC patients.  
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 27 of 71 
5.1 
Part A: Nivolumab Administration 
Nivolumab will be given every 2 weeks x 6 doses (2 cycles) at a dose of 240 mg Intravenously 
(IV) then every 3 weeks at a dose of 360 mg IV for 4 doses (2 cycles) followed by nivolumab 
480 mg IV every 4 weeks until toxicity, disease progression, SD at 48 weeks (end of Cycle 6) or 
complete response with a maximum of 96 total weeks (12 weeks induction, 84 weeks 
maintenance) Patients with disease progression (at any time) or SD at 48 weeks (end of Cycle 6) 
will be eligible to be considered for participation in Part B of the study.   
 
Part A 
Drug 
Dose  
Route3  
Schedule1 
Cycle Length 
Cycles/Weeks 
Nivolumab 
240 mg  
IV over 
30 minutes 
Day 1, 15, and 29 
6 weeks  
C1 and C2 
Weeks 1-12 
Nivolumab 
360 mg  
IV over 
30 minutes 
Day 1 and 22 
6 weeks  
C3 and C4  
Weeks 13-24 
Nivolumab 
480 mg 
IV over  
30 minutes 
Day 1, 29 and 57 
12 weeks 
C5-C10 
Weeks 25-96 
1 A window of ± 3 days may be applied to all study visits to accommodate observed holidays, inclement 
weather, scheduling conflicts etc. Date and time of each drug administration should be clearly documented in 
subject’s chart and electronic case report forms (eCRFs). 
2 Treatment will continue until toxicity, PD, SD at 48 weeks (end of Cycle 6) or CR with a maximum of 96 
weeks 
3. Infusion window of ± 10 minutes 
 
5.2 
Part B: Nivolumab + Ipilimumab 
Patients with Grade 3 toxicity on nivolumab monotherapy, (excluding endocrine toxicity), 
serious symptomatic disease that in the opinion of the site investigator requires immediate use of 
an alternative treatment approach or continued PR/CR will be excluded from enrolling in Part B.  
It is estimated that roughly half of the patients accrued to the first line treatment will go on to 
enroll in Part B.  Part B treatment is encouraged to start within 7 weeks of the last dose of Part A 
study drug, although there is no limit to the interval so long as there is no intervening systemic 
treatment for the metastatic RCC.  
 
Ipilimumab will be given 1 mg/kg every 3 weeks together with nivolumab 3 mg/kg every 3 
weeks for up to 4 doses. NOTE: ipilimumab/nivolumab combination treatment must be 
completed by week 16 even if < 4 doses are administered.  Nivolumab will revert to 360 mg 
every 3 weeks after the completion of combination treatment with ipilimumab for 4 doses (2 
cycles) followed by nivolumab 480 mg IV every 4 weeks until toxicity, disease progression or a 
maximum of 60 total weeks (12 weeks induction, 48 weeks maintenance) beginning week 13 to 
19 of Part B depending on how long it takes to recover from any side effects related to 
combination therapy. Patients may be dosed no less than 18 days from the previous dose of drug; 
and dosed up to 3 days after the scheduled date, if necessary. 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 28 of 71 
Part B 
Drug1 
Dose  
Route4  
Schedule3 
Cycle Length 
Cycles/Weeks 
Nivolumab 
3 mg/kg  
IV over 
30 minutes 
Day 1 and 22  
6 weeks  
C1 and C2 
Weeks 1-12 
Ipilimumab 
1mg/kg 
IV over 
30 minutes 
Nivolumab 
360 mg 
IV over 
30 minutes 
Day 1 and 22 
6 weeks 
C3 and C4  
Weeks 13-24 
Nivolumab 
480 mg  
IV over  
30 minutes 
Day 1, 29 and 57 
12 weeks  
C5-C7 
Weeks 25-60 
1 When study drugs (ipilimumab and nivolumab) are to be administered on the same day, separate infusion bags 
and filters must be used for each infusion. It is recommended that nivolumab be administered first. The second 
infusion will always be ipilimumab, and will start approximately 30 minutes after completion of the nivolumab 
infusion 
2 The dosing calculations should be based on the body weight where applicable. Institutional standards for 
recalculating the dose based on weight changes should be used. All doses should be rounded up or to the nearest 
milligram per institutional standard. 
3 A window of ± 3 days may be applied to all study visits to accommodate observed holidays, inclement weather, 
scheduling conflicts etc. Date and time of each drug administration should be clearly documented in subject’s 
chart and electronic case report forms (eCRFs). 
4 Infusion window of ± 10 minutes 
 
5.2 
Concomitant Medications 
 
5.2.1 Allowed Concomitant Medications 
All treatments that the investigator considers necessary for a subject’s welfare may be 
administered at the discretion of the investigator in keeping with the community standards of 
medical care. 
 
5.2.2 Prohibited Concomitant Medications  
Concomitant systemic or local anti-cancer medications or treatments are prohibited in this study 
while receiving ipilimumab/nivolumab treatments.  
 
Patients may not use any of the following therapies during the study: 
 Any non-study anti-cancer agent (investigational or non-investigational) 
 Any other investigational agents 
 Immunosuppressive agents (except as needed to treat toxicities that develop on therapy) 
 Physiologic replacement doses of corticosteroids are permitted if required 
 Any non-oncology vaccine therapies used for the prevention of infectious diseases (for up 
to 30 days prior to or after any dose of study drug) 
NOTE: Patients are permitted to receive the seasonal influenza vaccine. If seasonal 
influenza vaccine is considered, killed vaccines are mandatory. 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 29 of 71 
6. 
TOXICITIES AND DOSE DELAYS 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03 will be used to 
grade adverse events.  
 
Subjects enrolled in this study will be evaluated clinically and with standard laboratory tests 
before and at regular intervals during their participation in this study as specified in Study 
Calendar & Evaluations. 
 
Subjects will be evaluated for adverse events (all grades), serious adverse events, and adverse 
events requiring study drug interruption or discontinuation as specified in Study Calendar & 
Evaluations.   
 
6.1 
Dose Delays/Dose Modifications 
There will be no dose modifications permitted. Dose reductions or dose escalations are not 
permitted. 
 
6.1.1  Dose Delay Criteria 
Dose delay criteria apply for all drug-related adverse events (regardless of whether or not the 
event is attributed to nivolumab, ipilimumab or both). Study drugs (both agents if on induction 
phase of Part B) must be held/omitted until treatment can resume.  Please see Appendix A for 
AE management guidelines. 
 
Nivolumab and ipilimumab administration should be omitted for the following: 
 Any Grade ≥ 2 non-skin, drug-related adverse event, with the following exceptions: 
o Grade 2 drug-related fatigue or laboratory abnormalities that do not require a 
treatment delay (with the exception of Grade 3 AST, ALT or total bilirubin in 
patients with normal baseline values-see below).  
 Any Grade 3 skin, drug-related adverse event 
 Any Grade 3 drug-related laboratory abnormality, with the following exceptions: 
o Grade 3 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis do not require a dose delay. It is 
recommended to consult with the principal investigator for Grade 3 amylase or 
lipase abnormalities. 
o If a subject has a baseline AST, ALT, or total bilirubin that is within normal 
limits, delay dosing for drug-related Grade ≥ 2 toxicity 
o If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity 
range, delay dosing for drug-related Grade ≥ 3 toxicity 
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment 
of the site investigator, warrants delaying the dose of study medication. 
 
6.1.2 Criteria to Resume Treatment 
Subjects may resume treatment with study drugs when the drug-related AE(s) resolve to Grade ≤ 
1 or baseline value, with the following exceptions: 
 Subjects may resume treatment in the presence of Grade 2 fatigue  
 Subjects who have not experienced a Grade 3 drug-related skin AE may resume 
treatment in the presence of Grade 2 skin toxicity  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 30 of 71 
 Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose delays for 
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in 
the presence of Grade 2 AST/ALT OR total bilirubin 
 Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting 
discontinuation parameters (Section 6.3.3) should have treatment permanently 
discontinued 
 Drug-related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline 
before treatment is resumed 
 Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment 
 
If the criteria to resume treatment are met, the subject should restart treatment at the next 
scheduled timepoint per protocol (i.e., missed doses are NOT made up).  
 
If treatment is delayed > 6 weeks, (from the first missed dose) the subject should be permanently 
discontinued from study therapy, except as specified in discontinuation section below. 
 
6.1.3 Discontinuation Criteria 
Treatment should be permanently discontinued for the following: 
 Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to 
topical therapy and does not improve to Grade 1 severity within the re-treatment period 
OR requires systemic treatment  
 Any Grade 3 non-skin, drug-related adverse event lasting > 7 days, with the following 
exceptions for drug-related laboratory abnormalities, uveitis, pneumonitis, 
bronchospasm, diarrhea, colitis, neurologic adverse event, hypersensitivity reactions, and 
infusion reactions 
o Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic adverse event, hypersensitivity reaction, or infusion reaction of any 
duration requires discontinuation (NOTE: Subjects with Grade 3 diarrhea or 
colitis while on Part B ipilimumab/nivolumab combination therapy could resume 
nivolumab alone if toxicity resolves to at least Grade 1 off of immunosuppressive 
drugs by end of week 16. Nivolumab monotherapy cannot start until toxicity is 
resolved to at least Grade 1 off immunosuppression x 2 weeks and cannot begin 
before week 13 or after week 19.  
 Grade 3 drug-related laboratory abnormalities do not require permanent treatment 
discontinuation except those noted below 
o Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding  
o Any drug-related liver function test (LFT) abnormality that meets the following 
criteria require discontinuation:  
 AST or ALT > 8 x ULN 
 Total bilirubin > 5 x ULN 
 Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 31 of 71 
 Any Grade 4 drug-related adverse event or laboratory abnormality, except for the 
following events which do not require discontinuation: 
o Isolated Grade 4 amylase or lipase abnormalities that are not associated with 
symptoms or clinical manifestations of pancreatitis and: 
 Decrease to < Grade 4 within 2 weeks of onset in the absence of 
immunosuppressive therapy.  
 Decrease to < Grade 4 and maintain < Grade 4 for a minimum of 1 week 
after stopping immunosuppressive therapy. 
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated 
with clinical sequelae and are corrected with supplementation/appropriate 
management within 72 hours of their onset 
 Any dosing interruption lasting > 6 weeks (from scheduled dose) with the following 
exceptions: 
o Dosing interruptions to allow for prolonged steroid tapers to manage drug-related 
adverse events are allowed. Prior to re-initiating treatment in a subject with a 
dosing interruption lasting > 6 weeks, the sponsor-investigator must be consulted. 
Tumor assessments should continue as per protocol even if dosing is interrupted 
o Dosing interruptions > 6 weeks that occur for non-drug-related reasons may be 
allowed if approved by the sponsor-investigator. Prior to re-initiating treatment 
in a subject with a dosing interruption lasting > 6 weeks, the Principal 
Investigator must be consulted. Tumor assessments should continue as per 
protocol even if dosing is interrupted. 
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment 
of the site investigator, presents a substantial clinical risk to the subject with continued 
nivolumab or ipilimumab dosing 
 
6.2 
Treatment of Nivolumab or Ipilimumab Related Infusion Reactions 
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, it is 
unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such 
a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritis, 
arthralgias, hypo- or hypertension, bronchospasm, or other symptoms.  
 
All Grade 3 or 4 infusion reactions should be reported as an SAE if criteria are met. Infusion 
reactions should be graded according to NCI CTCAE v4.03 guidelines. 
 
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines as appropriate: 
 
 Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not 
indicated).  Remain at bedside and monitor subject until recovery from symptoms. The 
following prophylactic premedications are recommended for future infusions:  
o Diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen) at least 30 minutes before additional nivolumab administrations. 
 Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal anti-
inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 32 of 71 
medications indicated for 24 hours).  Stop the nivolumab or ipilimumab infusion, begin 
an IV infusion of normal saline, and treat the subject with diphenhydramine 50 mg IV (or 
equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen); remain at bedside and 
monitor subject until resolution of symptoms. Corticosteroid or bronchodilator therapy 
may also be administered as appropriate. If the infusion is interrupted, then restart the 
infusion at 50% of the original infusion rate when symptoms resolve; if no further 
complications ensue after 30 minutes, the rate may be increased to 100% of the original 
infusion rate. Monitor subject closely. If symptoms recur, then no further nivolumab or 
ipilimumab will be administered at that visit. Administer diphenhydramine 50 mg IV, and 
remain at bedside and monitor the subject until resolution of symptoms. The amount of 
study drug infused must be recorded on the electronic case report form (eCRF). The 
following prophylactic pre-medications are recommended for future infusions:  
o Diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen) should be administered at least 30 minutes before additional 
nivolumab or ipilimumab administrations. If necessary, corticosteroids 
(recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be 
used. 
 Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence 
of symptoms following initial improvement; hospitalization indicated for other clinical 
sequelae [eg, renal impairment, pulmonary infiltrates]). Grade 4: (life threatening; pressor 
or ventilatory support indicated).  Immediately discontinue infusion of nivolumab or 
ipilimumab. Begin an IV infusion of normal saline, and treat the subject as follows. 
Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 1:1,000 solution for 
subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for 
IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg 
IV (or equivalent), as needed. Subject should be monitored until the investigator is 
comfortable that the symptoms will not recur. Nivolumab or ipilimumab will be 
permanently discontinued.  Site investigators should follow their institutional guidelines 
for the treatment of anaphylaxis. Remain at bedside and monitor subject until recovery 
from symptoms. In the case of late-occurring hypersensitivity symptoms (eg, appearance 
of a localized or generalized pruritis within 1 week after treatment), symptomatic 
treatment may be given (eg, oral antihistamine, or corticosteroids). 
 
6.3 
Protocol Therapy Discontinuation 
In addition to discontinuation from therapy related to toxicities as outlined above, a subject will 
also be discontinued from protocol therapy and followed per protocol under the following 
circumstances outlined below.  The reason for discontinuation of protocol therapy will be 
documented on the electronic case report form (eCRF)   
 
Documented disease progression NOTE: Repeat scan should be performed in 4-6 weeks 
to confirm PD. A subject may be granted an exception to continue on treatment with 
confirmed radiographic progression if clinically stable or clinically improved. If PD 
confirmed patient can move to Part B and or go off study treatment.   
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 33 of 71 
 
Completed 96 weeks of treatment with nivolumab (Part A) or 60 weeks of (nivolumab + 
ipilimumab for 12 weeks followed by nivolumab monotherapy for up to 48 weeks) (Part 
B).  NOTE: 96 or 60 weeks of study medication are calculated from the date of first dose 
of each Part. 
 
Site investigator determines a change of therapy would be in the best interest of the 
subject 
 
Subject or legal representative (such as a parent or legal guardian) withdraws consent and 
requests to discontinue protocol therapy, whether due to unacceptable toxicity or for 
other reasons 
o In a subject decides to prematurely discontinue protocol therapy (“refuses 
treatment”), the subject should be asked if he or she may still be contacted for further 
scheduled study assessments. The outcome of that discussion should be documented 
in both the medical records and in the eCRF. 
 
Female subject becomes pregnant 
 Unacceptable adverse experiences  
 Intercurrent illness that prevents further administration of treatment 
 
Protocol therapy is interrupted for > 6 weeks (calculated from the date of the first missed 
dose). Any potential exceptions to this criterion must be discussed with and approved by 
the study chair.  
 
Noncompliance with protocol treatment or procedure requirements 
 
The subject is lost to follow-up 
 
Administrative reasons 
 
6.2 
Protocol Discontinuation  
If a subject decides to discontinue from the protocol (and not just from protocol therapy) all 
efforts should be made to complete and report study assessments as thoroughly as possible. A 
complete final evaluation at the time of the subject’s protocol withdrawal should be made with 
an explanation of why the subject is withdrawing from the protocol. If the reason for removal of 
a subject from the study is an adverse event, it will be recorded on the eCRF. 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 34 of 71 
7. 
STUDY CALENDAR & EVALUATIONS  
 
Screening 
Part A (± 3 days)  
Part B (± 3 days) 
End of 
Treatment 
(EOT) 
Follow 
Up12 
Induction 
Maintenance 
Prior 
to  
Part 
B 
Induction 
Maintenance 
Study Evaluation 
 
Cycle = 6 weeks  
Cycle = 
12 weeks 
Cycle = 6 weeks 
Cycle = 
12 weeks 
Safety 
Visits 
± 7 days11 
C1-C2 
C3-C4 
C5-C10 
C110-C2 
C3-C4 
C5-C7 
-28 
days 
-14 
days 
D
1 
D 
15/29 
D  
1 
D 
22 
D  
1 
D  
29/57 
-28 
days 
D  
1 
D 
22 
D
1 
D 
22 
D 
1 
D 
29/57 
D 
30 
D 
100 
± 14 
days 
REQUIRED ASSESSMENTS 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History/Smoking history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis and Staging 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Exam1 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Vital signs/ECOG PS Status1 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
AEs & concomitant medications 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
LABORATORY ASSESSMENTS 
Complete Blood Cell Count with 
diff (CBC)2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Comprehensive Metabolic Profile 
(CMP)2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Amylase, Lipase, LDH, CPK3 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
X 
 
X 
 
X 
 
 
HBV, HCV3 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid Function (TSH)3 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
X 
 
X 
 
X 
 
 
Pregnancy test (serum or urine)4  
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
DISEASE ASSESSMENT 
CT of chest5 
X 
 
 
 
X5 
 
X5 
 
X 
 
 
X5 
 
X5 
 
 
 
X5 
CT or MRI of abdomen and pelvis5 
X 
 
 
 
X5 
 
X5 
 
X 
 
 
X5 
 
X5 
 
 
 
X5 
TREATMENT EXPOSURE 
Nivolumab6 
 
 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
 
 
 
Ipilimumab6 
 
 
 
 
 
 
 
 
 
X 
X 
 
 
 
 
 
 
 
SPECIMEN COLLECTION  
Whole Blood for Somatic Testing7 
 
 
C1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMCs and plasma 7 
 
 
X7 
 
X7 
 
X7 
 
X7 
 
 
 
 
 
 
 
 
 
Archival Tumor Tissue8 
X8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fresh Tissue8 
 
X8 
 
 
 
 
 
 
X8 
 
 
 
 
 
 
 
 
 
SPECIMEN BANKING 
Whole Blood, Plasma and Serum9 
 
 
C1 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
FOLLOW UP 
Survival Status,Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 35 of 71 
Key to Footnotes  
 
1. If the screening physical exam is conducted within 24 hours of dosing on Day 1, then a single examination may count as both the screening and pre-dose 
evaluation. Vitals required are temperature, pulse, respiratory rate, blood pressure, and oxygen saturation.  
2. Hematology Labs should include CBC with differential (hemoglobin, hematocrit, white blood cells, platelets, neutrophils, lymphocytes, eosinophils and 
monocytes). Additional draws must be incorporated when monitoring recovery from any hematologic AE.  Chemistry Labs should include albumin, BUN, 
creatinine, ALT, AST, bilirubin serum alkaline phosphatase, glucose, total protein, sodium, potassium, chloride, HCO3, calcium.  Labs should be performed 
on the day of treatment but may be drawn up to 72 hours before to ensure return of results prior to dosing. 
3. Other labs to be drawn: amylase, lipase, LDH, direct bilirubin (only if total bilirubin is elevated), uric acid and CPK Day 1 of every Cycle during treatment.  
Thyroid function will be monitored Day 1 of each cycle during treatment. TSH will be monitored and T3 and T4 (free versus total) should be drawn at site 
investigators discretion. It is suggested that if TSH is elevated T3 and T4 values may be done. At screening, testing should be performed for hepatitis C 
antibody and HBs Ag utilizing local standard informed consent procedures prior to this laboratory collection. These tests could be repeated later during the 
course of the study if clinically indicated.  
4. Women of child-bearing potential must have a negative serum or urine pregnancy test within 24 hours prior to treatment with nivolumab and again at 
crossover to Part B for screening purposes. 
5. Non-CNS Imaging should include a chest, abdomen and pelvis CT. Imaging of other sites should be obtained when clinically indicated. If follow up scans 
indicate partial or complete response, a repeat confirmatory scan should be obtained within 12 weeks (but no sooner than 6 weeks). Subjects with equivocal 
disease progression (e.g. a new lesion in the setting of major disease regression and the absence of or improvement in disease related symptoms) should have a 
scan confirming disease progression 4-6 weeks following the initial scan showing RECIST defined PD.  Part A imaging will occur at baseline within 4 weeks 
of C1D1 of Part A, then at week 12 (after C1 and C2 of Part A Induction), week 18 (after C3 and before C4 of Part A Maintenance), week 24 (after C4 of Part 
A maintenance) and then every 12 weeks (± 1 week).  Patients with symptomatic and radiographic PD will not require a confirmatory scan before proceeding 
to Part B of this study. Following crossover, imaging and calendar will be reset at Cycle 1.  Part B imaging will occur at baseline within 4 weeks prior to 
crossover, then at week 12 (after C1 and C2 of Part B Induction), week 18 (after C3 and before C4 Part B Maintenance), week 24 (after C4 Part B 
Maintenance) and then every 12 weeks (± 1 week). Every 12 weeks radiology imaging will occur if the patient is < 2 years from study entry (or < 2 years from 
crossover), then radiology imaging will occur every 6 months (± 4 weeks) until 5 years from study entry. If tumor assessments are available for subjects who 
have not yet experienced progressive disease (PD) at the time treatment is discontinued, the follow-up tumor evaluations will be documented in the eCRF until 
PD or death is confirmed, or until another treatment is initiated.   
6. 1 Cycle= (6 weeks) for Part A (induction and maintenance C3 and C4) and Part B (induction and maintenance C3 and C4). 1 Cycle = 12 weeks for Part A 
maintenance C 5-10 and Part B maintenance C5-C7. Treatment and follow-up schedule is the same for either nivolumab monotherapy or 
ipilimumab/nivolumab combination. Patients responding in Part A will receive treatment at most through Cycle 10 (week 96).  Patients crossing over to Part B 
will receive treatment at most through Cycle 7 (week 60) from start of Part B.  They will then have treatment stopped and be followed until disease progression 
or study closure. Once confirmed progression is confirmed or stable disease for 48 weeks (end of Cycle 6), nivolumab monotherapy will be discontinued for 
Part A and the patient will undergo evaluation for Part B treatment.  
7. Mandatory Samples: Peripheral blood for somatic baseline testing will be collected prior to treatment on C1D1 Part A.  PBMCs and plasma are preferred (or 
whole blood) for TCR assay and will be collected prior to treatment (C1D1), C3D1, C5D1 (Part A) and at time of progression (Prior to Part B). See 
Correlative Laboratory Manual (CLM) for additional details. 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 36 of 71 
8. Archival tissue of a metastatic lesion obtained within 1 year prior to study registration (within 4 weeks preferred) and tumor tissue from nephrectomy is 
required if available.  In addition to archival tissue of a metastatic lesion and nephrectomy, patients must have at least one site of disease (not including bone 
metastases) accessible for biopsy.  If biopsy/resection of a new lesion or primary tumor and slow freezing of fresh tissue for single cell RNAseq study (as 
specified in the CLM) is not feasible, the subject is not eligible for the study. All biopsies must be core needle or excisional. Fine needle aspirate is not 
acceptable. NOTE: The tissue collected from a surgical resection or multiple core biopsies of either a metastatic lesion or primary tumor for the slow freezing 
of fresh tissue after the patient has signed consent for the study could also be used for collecting the FFPE specimens. See Correlative Laboratory Manual for 
complete details.  
9. For Part A only: Whole blood will be collected prior to treatment C1D1. Whole blood for plasma and serum prior to treatment on C1D1and at the D30 end of 
treatment visit. All samples will be banked for unspecified cancer related research (optional). See Correlative Laboratory Manual for complete details. 
10. Patients on Part B should be contacted weekly during Cycles 1 and 2. If a patient reports symptoms at any time during these cycles or abnormal labs are noted 
at the regularly scheduled visits (C1 D22, C2 D1 or D22) then more frequent laboratory testing and clinic visits are encouraged.. This decision is at the 
discretion of the site investigator. 
11. An End of Treatment (EOT) visit should occur 30 and 100 days (± 7 days) from last dose of study drug. For patients experiencing toxicities, additional visits 
may be necessary and may occur occur every 2 weeks (± 3 days) until toxicities resolve, are stable, or start of new systemic therapy.  Depending upon the 
toxicity, the every 2-week assessment may be accomplished via phone call, email or other avenues as appropriate.  Mode of assessment will be at site 
investigator’s discretion. If patients have progressive disease as the reason for discontinuation from study, the D100 may be a phone call. 
12. Follow up is for subjects that have discontinued study treatment. Subjects should be followed every 3 months if < 3 years from study registration and every 6 
months if 3-5 years from study registration. Patients who develop disease progression on Part B or on Part A (if ineligible for Part B) will be followed for 
survival only. Follow up may be accomplished via clinic visit, phone call, or other avenues as appropriate. A window of ± 14 days will be applied to follow up.  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 37 of 71 
8. 
BIOSPECIMEN STUDIES AND PROCEDURES 
A variety of factors that may impact the immunomodulatory properties and efficacy of 
nivolumab or nivolumab-ipilimumab combination will be investigated in tumor tissue and from 
all registered subjects prior to Part A and in those patients going onto to Part B as outlined in 
Section 7.  
 
8.1 
Analyses 
 
8.1.1 Assessment of PD-L1 Expression on Tumor and Infiltrating Mononuclear Cells  
Tumor cell surface PD-L1 expression on primary tumor specimens serves as a potential 
predictive biomarker of durable response to PD-1 antibody therapy [17]. However, data from 
several recent studies suggest that IHC staining for PD-L1 alone fails to identify all responders to 
PD-1 blocking Abs [39, 40]. Some patients with PD-L1 negative tumors respond to PD-1 
pathway blockade, while many patients with PD-L1 positive tumors fail to do so. Interestingly, 
in melanoma, the benefit of combined PD-1 and CTLA-4 blockade versus PD-1 alone appeared 
to be greatest in patients with negative PD-L1 tumor expression [22]. We will test whether PD-
L1 status is indeed predictive of higher response to combined checkpoint blockade. 
 
8.1.2 Assessment of Tumor IFN Gamma Signature, Mutational Load, and Maximum 
Fuhrman Grade  
In patients with metastatic RCC, treatment with nivolumab resulted in increased expression of 
genes indicative of Th1-type inflammatory response and cytotoxic T cell activation, such as 
ICOS, interferon-gamma, granzymes, and perforin [48]. In addition, CXCL9 and CXCL10, two 
interferon-gamma-regulated chemokines that in turn regulate trafficking of T cells, and are both 
prognostic [49] and predictive of response to ipilimumab [50]. We propose to study tumor 
interferon-gamma signature using RNA sequencing as a marker of response to PD-1 and PD-
1/CTLA-4 blockade. 
 
Accumulating evidence shows that anti-tumor immune responses focus on neoantigens generated 
by tumor mutation, and responsiveness to immunotherapy correlates with neoantigen burden. 
[51, 52]. Mutational load has been correlated with response to CLTA-4 and PD-1 blockade in 
melanoma [53, 54] and multiple other tumor types [55-57]. These data motivate us to perform a 
systematic analysis of mutation burden and neoantigen load using Whole Exome Sequencing 
(WES). We will explore potential neoantigens in subsets of responding and non-responding 
patients. We will also evaluate changes in neoantigen load at the time of resistance compared 
with baseline samples. 
 
Tumor cell PD-L1 expression has been correlated with higher Fuhrman nuclear grade [26]. In a 
cohort of mRCC patients treated with PD-L1 antibody, overall response rate was slightly higher 
in patients with Fuhrman grade 4 and/or sarcomatoid histology (ORR 22% versus 15% in the 
overall cohort) [58]. Therefore, we will assess Fuhrman grade and sarcomatoid histology as 
predictors of response.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 38 of 71 
8.1.3 Investigation of Mechanisms of Innate and Acquired Resistance to Nivolumab 
Therapy 
Resistance to PD-1 blockade may occur as as primary or secondary event. In order to elicit a 
successful anti-tumor immune response, tumor neoantigens must be presented by antigen-
presenting cells to CD8+ T cells via major histocompatibility complex class I (MHC-I) 
molecules. Then, lymphocytes must be primed and activated. Lymphocytes must be trafficked to 
the tumor and subsequently infiltrate the tumor, then they must recognize the tumor cells, and 
finally they must produce cytotoxic effect. “Non-inflamed” tumors, those that lack tumor-
infiltrating lymphocytes, may have a defect in early steps of the generation of this immune 
response and may have primary resistance to PD-1 blockade. “Inflamed” tumors, those that do 
contain tumor-infiltrating lymphocytes, may have defects in later steps such as loss or alteration 
of MHC-I [59-61]. Multiple other checkpoints may become activated [62-65] Finally other 
immunosuppressive cells in the tumor microenvironment may blunt the T-cell response. We will 
perform exploratory analyses to evaluate these mechanisms further, including exploratory 
analyses of immune cells using immunosequencing.  
 
8.2. 
Tissue Collections 
SEE CLM FOR ADDITIONAL DETAILS. 
 
8.2.1 Archival Tumor Tissue 
Archival tissue of a metastatic lesion (from core needle or excisional biopsy) obtained within 1 
year prior to study registration (within 4 weeks preferred) and tumor tissue from nephrectomy is 
required if available. Confirmation of sufficient archival tissue must be obtained prior to C1D1 
and shipped to the appropriate lab by end of Cycle 2.  Biopsies must be core needle or excisional 
biopsies of primary tumor or visceral or lymph node metastases. Fine needle aspirates of any 
metastatic site, and biopsies of bone lesions are not acceptable.   
 
8.2.2 Pre-Treatment Tumor Tissue 
Patients must have at least one site of disease (not including bone metastases) accessible for 
biopsy after confirmation of eligibility/consent and prior to initiation of treatment.  If 
biopsy/resection of a new lesion or primary tumor and slow freezing of fresh tissue for single cell 
RNAseq study (as specified in the CLM) is not feasible, the subject is not eligible for the study. 
All biopsies must be core needle or excisional. Fine needle aspirate biopsies are not acceptable, 
nor are biopsies of non soft tissue components of bone metastases. NOTE: The tissue collected 
from a surgical resection or multiple core biopsies of either a metastatic lesion or primary tumor 
for the slow freezing of fresh tissue after the patient has signed consent for the study could also 
be used for collecting the FFPE specimens  
 
8.2.3 Tumor Tissue- At Progression 
Tumor biopsy prior to combination treatment is mandatory. If a biopsy/resection of a new lesion 
or primary tumor and slow freezing of fresh tissue for single cell RNAseq study (as specified in 
the CLM) is not feasible, the subject is not eligible for the study. All biopsies must be core 
needle or excisional. Fine needle aspirate biopsies are not acceptable, nor are biopsies of non soft 
tissue components of bone metastases.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 39 of 71 
8.2.4 Tumor Tissue for RNAseq 
Part of the tissue collected prior to C1D1 and at progression will be used for single cell RNAseq 
analysis. This analysis will be funded through the Department of Defense (DoD) via a proposal 
entitled, "Using Single Cell Transcriptomics to Understand Tumor and Immune Heterogeneity 
Driving Resistance and to Rationally Select Immune Therapy in Advanced RCC.” In addition to 
the data from the sample analysis, the DoD will have access to de-identified subject data such as 
response outcomes. 
 
8.3 
Peripheral Blood Samples 
 
8.3.1 Mandatory Whole Blood for Somatic Baseline Testing  
Whole blood will be collected prior to treatment Cycle 1 Day 1 for somatic testing. 
 
8.3.2 Mandatory PBMCs and Plasma (preferred) or Whole Blood for TCR analysis  
Whole blood for PBMCs and plasma isolation for TCR analysis should be collected at baseline 
(C1D1), C3D1, C5D1 and at time of disease progression.  If PBMCs cannot be processed on site, 
whole blood may be collected. See CLM for collection and processing instructions. 
 
8.3.3 Optional Whole Blood, Plasma and Serum for Banking  
Subject consent will be obtained for additional samples to be collected for future unspecified 
cancer related research studies. HCRN will manage the banked samples. Samples will be banked 
indefinitely in the HCRN Biorepository. 
 
This includes: 
 Pre whole blood: Whole blood for banking will be collected for Part A only; prior to 
treatment Cycle 1 Day 1. 
 Pre and Post Treatment plasma and serum: Whole blood for plasma and serum will be 
collected for Part A only; prior to treatment on Cycle 1 Day and at the D30 end of 
treatment visit. 
 
8.4 
Storage of Biospecimens 
All specimens not exhausted in planned correlative studies for this trial will be banked for future 
unspecified cancer related research. Patient consent will be obtained for banking of these 
samples. 
 
8.5 
Confidentiality of Biospecimens 
Samples that are collected will be identified by a subject’s sequence ID at the time of registration 
to the trial. Any material issued to collaborating researchers will be anonymized and only 
identified by the subject’s sequence ID. 
 
9. 
CRITERIA FOR DISEASE EVALUATION 
For the purposes of this study, subjects should be evaluated for response every 12 weeks.  Non-
CNS Imaging should include a chest, abdomen and pelvis CT. Imaging of other sites should be 
obtained when clinically indicated. If follow up scans indicate partial or complete response, a 
repeat confirmatory scan should be obtained within 12 weeks (but no sooner than 6 weeks). 
Subjects with equivocal disease progression (e.g. a new lesion in the setting of major disease 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 40 of 71 
regression and the absence of or improvement in disease related symptoms) should have a scan 
confirming disease progression 4-6 weeks following the initial scan showing RECIST defined 
PD.  Patients with symptomatic and radiographic PD will not require a confirmatory scan before 
proceeding to Part B of this study.  The date of the first scan will be the documented date of 
progression. 
 
Response and progression will be evaluated in this study using the international criteria proposed 
by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) 
[Eur J Ca 45:228-247, 2009] and irRECIST. Changes in the largest diameter (unidimensional 
measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph 
nodes are used in RECIST. 
 
The following general principles must be followed: 
1. To assess objective response, it is necessary to estimate the overall tumor burden at 
baseline to which subsequent measurements will be compared. All baseline evaluations 
should be performed as closely as possible to the beginning of treatment and never more 
than four weeks before registration. 
2. Measurable disease is defined by the presence of at least one measurable lesion. 
3. All measurements should be recorded in metric notation by use of a ruler or calipers.  
4. The same method of assessment and the same technique must be used to characterize 
each identified lesion at baseline and during follow-up.  
 
9.1 
Definitions 
 
9.1.1 Evaluable for Objective Response 
Only those subjects who have measurable disease present at baseline, have received at least one 
cycle of therapy, and have had their disease re-evaluated will be considered evaluable for 
response. These subjects will have their response classified according to the definitions stated 
below.  Those subjects that are inevaluable will not be replaced. 
 
(NOTE: Subjects who exhibit objective disease progression prior to the end of Cycle 1 will also 
be considered evaluable.) 
 
9.1.2 Evaluable Non-Target Disease Response 
Patients who have lesions present at baseline that are evaluable but do not meet the definitions of 
measurable disease, have received at least one cycle of therapy, and have had their disease re-
evaluated will be considered evaluable for non-target lesion assessment. The response 
assessment is based on the presence, absence, or unequivocal progression of the lesions. 
 
9.2 
Disease Parameters 
 
9.2.1 Measurable Disease 
Measurable disease is defined as the presence of at least one measurable lesion. Measurable 
lesions are defined as those that can be accurately measured in at least one dimension (longest 
diameter to be recorded) as >20 mm by chest x-ray, as >10 mm with CT scan, or >10 mm with 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 41 of 71 
calipers by clinical exam. All tumor measurements must be recorded in millimeters (or decimal 
fractions of centimeters). 
 
NOTE: Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable. If the site investigator thinks it appropriate to include them, the 
conditions under which such lesions should be considered must be defined in the protocol. 
 
9.2.2 Malignant Lymph Nodes 
To be considered pathologically enlarged and measurable, a lymph node must be >15 mm in 
short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater 
than 5 mm). At baseline and in follow-up, only the short axis will be measured and followed. 
 
9.2.3 Non-measurable Lesions 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered non-measurable 
disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or 
MRI), are considered as non-measurable. Non-measurable also includes lesions that are < 20 mm 
by chest x-ray. 
 
NOTE:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts. ‘Cystic lesions’ thought to represent cystic metastases can be considered 
as measurable lesions, if they meet the definition of measurability described above. However, if 
non-cystic lesions are present in the same subject, these are preferred for selection as target 
lesions. 
 
9.2.4 Target Lesions 
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in which circumstance the next 
largest lesion which can be measured reproducibly should be selected. A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be 
calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the 
sum, then only the short axis is added into the sum. The baseline sum diameters will be used as 
reference to further characterize any objective tumor regression in the measurable dimension of 
the disease. 
 
9.2.5 Non-target Lesions 
All other lesions (or sites of disease) including any measurable lesions over and above the 5 
target lesions should be identified as non-target lesions and should also be recorded at baseline. 
Measurements of these lesions are not required, but the presence, absence, or in rare cases 
unequivocal progression of each should be noted throughout follow-up. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 42 of 71 
9.3 
Evaluation of Target Lesions 
NOTE: In addition to the information below, also see section 4.3.2 in the international criteria 
proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee, version 
1.1 (Eur J Cancer 45;2009:228-247) for special notes on the assessment of target lesions.  
 
Complete 
Response (CR) 
Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to 
<10 mm. To be assigned a status of complete response, changes in 
tumor measurements must be confirmed by a repeat assessment 
performed no less than six weeks after the criteria for response is 
met. 
Partial Response 
(PR) 
At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters.  To be assigned a 
status of partial response, changes in tumor measurements must be 
confirmed by a repeat assessment performed no less than six weeks 
after the criteria for response is met. 
Progressive 
Disease (PD) 
At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on study). In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. (NOTE:  the appearance of one or more 
new lesions is also considered progressions).  Subjects with 
equivocal disease progression (e.g. a new lesion in the setting of 
major disease regression and the absence of or improvement in 
disease related symptoms) should have a scan confirming disease 
progression 4-6 weeks following the initial scan showing RECIST 
defined PD.  Subjects may continue on protocol therapy until repeat 
scan confirms PD. If repeat scan does not confirm PD, subjects 
should proceed with treatment and evaluation as directed by the 
protocol with the confirmatory scan (if between 4 and 6 weeks from 
last scan) being counted as the 6 week interval scan. 
Stable Disease 
(SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diameters 
while on study.  NOTE: a change of 20% or more that does not 
increase the sum of the diameters by 5 mm or more is coded as stable 
disease). To be assigned a status of stable disease, measurements 
must have met the stable disease criteria at least once after study 
entry at a minimum interval of 24 weeks. 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 43 of 71 
9.4 
Evaluation of Non-Target Lesions 
 
Complete Response (CR) 
Disappearance of all non-target lesions.  All lymph nodes 
must be non-pathological in size (<10 mm short axis) 
Non-CR/ Non-PD 
Persistence of one or more non-target lesion(s)  
Progressive Disease (PD) 
Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target lesions. 
Unequivocal progression should not normally trump target 
lesion status. It must be representative of overall disease 
status change, not a single lesion increase.  When the 
subject also has measurable disease, there must be an 
overall level of substantial worsening in non-target disease 
such that, even in the presence of SD or PR in target 
disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.  A modest 
“increase” in the size of one or more non-target lesions is 
usually not sufficient to qualify for unequivocal 
progression status. The designation of overall progression 
solely on the basis of change in non-target disease in the 
face of SD or PR of target disease will therefore be 
extremely rare.  When the subject only has non-
measurable disease, the increase in overall disease burden 
should be comparable in magnitude to the increase that 
would be required to declare PD for measurable disease: 
i.e., an increase in tumor burden from “trace” to “large”, 
an increase in nodal disease from “localized” to 
“widespread”, or an increase sufficient to require a change 
in therapy. 
Although a clear progression of “non-target” lesions only 
is exceptional, the opinion of the site investigator should 
prevail in such circumstances, and the progression status 
should be confirmed at a later time by the review panel (or 
sponsor-investigator). 
 
9.5 
Evaluation of New Lesions 
The appearance of new lesions constitutes Progressive Disease (PD).  A growing lymph node 
that did not meet the criteria for reporting as a measurable or non-measurable lymph node at 
baseline should only be reported as a new lesion (and therefore progressive disease) if it:  
 Increases in size to ≥ 15 mm in the short axis, or  
 There is new pathological confirmation that it is disease (regardless of size). New 
effusion or ascites that appears during treatment should only be reported as a new lesion 
(and therefore progressive disease) if it has cytological confirmation of malignancy. 
 
9.6 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence or non-protocol therapy (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). The patient’s best 
response assignment will depend on the achievement of both measurement and confirmation 
criteria. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 44 of 71 
9.7 
Evaluation of Best Overall Response 
 
Target 
Lesions 
Non-Target Lesions 
New 
Lesions* 
Overall 
Response 
Remarks 
CR 
CR 
No 
CR 
**** 
CR 
Non-CR/ Non-PD*** 
No 
PR 
**** 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD*** 
 or not all evaluated 
No 
PR 
SD 
Non-PD*** 
 or not all evaluated 
No 
SD 
Documented at least once 
≥ 24 weeks from study 
entry 
PD 
Any 
Yes or No 
PD 
No prior SD, PR or CR 
Any 
PD** 
Yes or No 
PD*** 
Any 
Any 
Yes 
PD 
*          See RECIST 1.1 manuscript for further details on what is evidence of a new lesion. 
**        In exceptional circumstances, unequivocal progression in non-target lesions may be 
accepted as disease progression. 
***     PD in non-target lesions should not normally trump target lesion status. It must be 
representative of overall disease status change, not a single lesion increase. Please 
refer to the Evaluation of Non-Target Lesions – Progressive Disease section for 
further explanation.  
****    To be assigned a status of partial or complete response, changes in tumor 
measurements must be confirmed by a repeat assessment performed no less than six 
weeks after the criteria for response is met. 
NOTE: Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be reported 
as “symptomatic deterioration.” Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
 
9.8 
Definitions for Response Evaluation – RECIST 1.1 
 
9.8.1 Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started). 
 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 45 of 71 
9.8.2 Duration of Stable Disease 
Stable disease is measured from the start of the treatment until the criteria for progression are 
met, taking as reference the smallest measurements recorded since the treatment started, 
including the baseline measurements.  
 
To be assigned a status of stable disease, measurements must have met the stable disease criteria 
at least once after study entry at a minimum interval of 24 weeks. 
 
9.8.3 Additional Criteria to Continue Treatment after Progression 
Patients may continue on protocol therapy until repeat scan confirms PD.  If repeat scan does not 
confirm PD, patients should proceed with treatment and evaluation as directed by the protocol 
with the confirmatory scan (if between 4 and 6 weeks from last scan) being counted as the 6 
week interval scan. 
 
9.8.4 Overall Survival 
Overall survival is defined by the date of registration to date of death from any cause. 
 
9.9 
Immune Related RECIST (irRECIST)  
PFS, ORR and duration of response per irRECIST are defined as specified for the respective 
endpoints using RECIST 1.1 above, with the exception that a confirmation assessment of PD (4-
6 weeks after the initial PD assessment) is required for subjects who remain on treatment 
following a documented PD per RECIST 1.1.  The first date of progression, confirmed on the 
subsequent imaging study, will be considered the date of progression. Subjects who discontinue 
treatment following a documented PD assessment per RECIST 1.1 will be counted as having 
disease progression on the date of the documented PD assessment.   
 
10. 
DRUG INFORMATION 
 
10.1 
Nivolumab 
Nivolumab was selected for dosage form development and is also referred to as BMS-936558-01 
or BMS-936558. Nivolumab is a soluble protein consisting of 4 polypeptide chains, which 
include 2 identical heavy chains and 2 identical light chains. 
Other Names  Nivolumab, BMS-936558, MDX1106, anti-PD-1 
Molecular Wt 146,221 daltons (143,619.17 daltons, protein portion) 
Appearance  Clear to opalescent, colorless to pale yellow liquid, few particulates may be 
present 
 
Solution pH  5.5 to 6.5 
 
10.1.1 Supplier/How Supplied 
Nivolumab Injection, 100 mg/10 mL (10 mg/mL)  
BMS will supply nivolumab at no charge to subjects participating in this clinical trial.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 46 of 71 
The site investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage/evidence of 
destruction of investigational product in accordance with the protocol and any applicable laws 
and regulations. 
 
10.1.2 Preparation  
Nivolumab Injection, 100 mg/10 mL (10 mg/mL). Nivolumab injection is to be administered as 
an IV infusion through a 0.2-micron to 1.2-micro pore size, low-protein binding in-line filter at 
the protocol-specified doses and infusion times. It is not to be administered as an IV push or 
bolus injection. Nivolumab injection can be infused undiluted (10 mg/mL) or diluted with 0.9% 
Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to protein concentrations as low 
as 0.35 mg/mL. Total infusion volume not to exceed 120 mL. During drug product preparation 
and handling, vigorous mixing or shaking is to be avoided. Instructions for dilution and infusion 
of nivolumab injection may be provided in the clinical protocol or investigator’s brochure. Care 
must be taken to assure sterility of the prepared solution as the product does not contain any 
antimicrobial preservative or bacteriostatic agent. No incompatibilities between nivolumab and 
polyvinyl chloride (PVC) and non-PVC/non-DEHP (di(2-ethylhexyl)phthalate) containers/IV 
components or glass bottles have been observed. 
 
10.1.3 Storage and Stability 
Nivolumab Injection, 100 mg/10 mL (10 mg/mL). Vials of nivolumab injection must be stored at 
2° to 8°C (36° to 46°F) and protected from light and freezing.   
 
Undiluted Nivolumab Injection and Diluted Nivolumab Injection in the IV Container. The 
administration of nivolumab infusion must be completed within 24 hours of preparation. If not 
used immediately, the infusion solution may be stored under refrigeration conditions (2°to 8°C, 
36°to 46°F) for up to 24 hours, and a maximum of 8 hours of the total 24 hours can be at room 
temperature (20° to 25°C, 68° to 77°F) and room light. The maximum 8 hour period under room 
temperature and room light conditions includes the product administration period. 
 
After final drug reconciliation, unused nivolumab vials should be disposed at the site following 
procedures for the disposal of anticancer drugs. Certificate of destruction for unused supply 
should be retained for BMS 
 
10.1.4 Handling and Disposal 
Preparation should be performed by trained personnel in accordance with good practices rules, 
especially with respect to asepsis. 
 
10.1.5 Dispensing 
Nivolumab must be dispensed only from official study sites and to eligible subjects under the 
supervision of the site investigator. Nivolumab should be stored in a secure area according to 
local regulations. It is the responsibility of the site investigator to ensure that study drug is only 
dispensed to subjects.   
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 47 of 71 
10.1.6 Adverse Events 
Please see the current Investigator’s Brochure for complete details regarding AEs of nivolumab. 
The most common side effects of nivolumab are: 
 Fatigue  
 Skin reactions: including rash, itching, hives, redness, and dry skin.  Toxic epidermal 
necrolysis, a potentially life threatening disease characterized by blistering and peeling of 
the top layer of skin resembling that of a severe burn, has occurred in one subject who 
received ipilimumab after nivolumab treatment. 
 Diarrhea 
 Nausea 
 Abdominal pain 
 Decreased appetite 
 Low red blood cells 
 Fever 
 Joint pain or stiffness 
 
10.2 
Ipilimumab 
Ipilimumab is a recombinant, human monoclonal antibody that binds to the CTLA-4. Ipilimumab 
is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. 
Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture. 
 
Bristol-Myers Squibb (BMS) will supply ipilimumab.  Ordering of ipilimumab will take place 
through the BMS vendor. 
 
10.2.1 Pharmacokinetics (PK) 
Ipilimumab as a single agent: The pharmacokinetics of ipilimumab was studied in 499 subjects 
with unresectable or metastatic melanoma who received doses of 0.3, 3, or 10 mg/kg 
administered once every 3 weeks for four doses. Peak concentration (Cmax), trough 
concentration (Cmin), and area under the curve (AUC) of ipilimumab were found to be dose 
proportional within the dose range examined. Upon repeated dosing of ipilimumab administered 
every 3 weeks, ipilimumab clearance was found to be time invariant, and minimal systemic 
accumulation was observed as evident by an accumulation index of 1.5-fold or less. Ipilimumab 
steady-state concentration was reached by the third dose. The following mean (percent 
coefficient of variation) parameters were generated through population PK analysis: terminal 
half-life of 14.7 days (30.1%); systemic clearance (CL) of 15.3 mL/h (38.5%); and volume of 
distribution at steady-state (Vss) of 7.21 L (10.5%). The mean (±SD) ipilimumab Cmin achieved 
at steady-state with the 3-mg/kg regimen was 21.8 mcg/mL (±11.2). 
 
Nivolumab in combination with ipilimumab: The geometric mean (%CV) CL, Vss, and terminal 
half-life of nivolumab were 10.0 mL/h (50.3%), 7.92 L (30.1%), and 24.8 days (94.3%), 
respectively. When administered in combination, the CL of nivolumab was increased by 24%, 
whereas there was no effect on the clearance of ipilimumab. When administered in combination, 
the clearance of nivolumab increased by 42% in the presence of anti-nivolumab antibodies. 
There was no effect of anti-ipilimumab antibodies on the clearance of ipilimumab.  
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 48 of 71 
Specific Populations: Cross-study analyses were performed on data from subjects with a variety 
of conditions, including 420 subjects with melanoma who received single or multiple infusions 
of ipilimumab at doses of 0.3, 3, or 10 mg/kg. The effects of various covariates on ipilimumab 
PKs were assessed in population pharmacokinetic analyses. 
 
Ipilimumab CL increased with increasing body weight; however, no dose adjustment of 
Ipilimumab is required for body weight after administration on a mg/kg basis. The following 
factors had no clinically meaningful effect on the CL of ipilimumab: age (range 26 to 86 years), 
gender, concomitant use of budesonide, performance status, HLA-A2*0201 status, positive anti-
ipilimumab antibody status, prior use of systemic anticancer therapy, or baseline lactate 
dehydrogenase (LDH) levels. The effect of race was not examined as there were insufficient 
numbers of subjects in non-Caucasian ethnic groups. 
 
Renal Impairment: Creatinine clearance at baseline did not have a clinically important effect on 
ipilimumab pharmacokinetics in subjects with calculated creatinine clearance values of 29 
mL/min or greater. 
 
Hepatic Impairment: Baseline AST, total bilirubin, and ALT levels did not have a clinically 
important effect on ipilimumab pharmacokinetics in subjects with various degrees of hepatic 
impairment. 
 
10.2.2 Preparation 
Ipilimumab is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow 
solution for intravenous infusion, which may contain a small amount of visible translucent-to-
white, amorphous ipilimumab particulates. It is supplied in single-use vials of 200 mg/40 mL 
Each milliliter contains 5 mg of ipilimumab and the following inactive ingredients: diethylene 
triamine penta acetic acid (DTPA) (0.04 mg), mannitol (10 mg), polysorbate 80 (vegetable 
origin) (0.1 mg), sodium chloride (5.85 mg), tris hydrochloride (3.15 mg), and Water for 
Injection, USP at a pH of 7. 
 
Do not shake product.  
Inspect parenteral drug products visually for particulate matter and discoloration prior to 
administration. Discard vial if solution is cloudy, there is pronounced discoloration (solution may 
have pale yellow color), or there is foreign particulate matter other than translucent-to white, 
amorphous particles. 
 
Preparation of Solution: 
 Allow the vials to stand at room temperature for approximately 5 minutes prior to 
preparation of infusion.  
 Withdraw the required volume of ipilimumab and transfer into an intravenous bag. 
 Dilute with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to 
prepare a diluted solution with a final concentration ranging from 1 mg/mL to 2 mg/mL. 
Mix diluted solution by gentle inversion.  
 Store the diluted solution for no more than 24 hours under refrigeration (2°C to 8°C, 36°F 
to 46°F) or at room temperature (20°C to 25°C, 68°F to 77°F).  
 Discard partially used vials or empty vials of ipilimumab. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 49 of 71 
10.2.3 Storage and Stability 
Store ipilimumab under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect vials 
from light. 
 
10.2.4 Administration 
Do not mix ipilimumab with, or administer as an infusion with, other medicinal products. Flush 
the intravenous line with 0.9% Sodium Chloride Injection, USP or 0.5% Dextrose Injection, USP 
after each dose. Administer diluted solution over 30 minutes (+/- 10 minutes) through an 
intravenous line containing a sterile, non-pyrogenic, low-protein-binding in-line filter. 
 
10.2.5 Handling and Disposal 
Accountability for investigational product is the responsibility of the investigator. The research 
pharmacy will maintain a careful record of the inventory and disposition of the agent using the 
NCI Drug Accountability Record Form (DARF) or another comparable drug accountability 
form.   
 
Qualified personnel, familiar with procedures that minimize undue exposure to themselves and 
the environment, should undertake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self-contained and protective environment. 
 
Drug should be destroyed at the site, after the investigator approves the drug destruction policy at 
the site. Drug will not be returned to BMS. Destruction will be documented in the Drug 
Accountability Record Form and certificate of destruction provided to BMS. 
 
10.2.6 Compatibility 
No incompatibilities between the nivolumab and ipilimumab have been observed. When both 
study drugs are to be administered on the same day, separate infusion bags and filters must be 
used for each infusion. Nivolumab is to be administered first. The nivolumab infusion must be 
promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab 
infusion. The second infusion will always be ipilimumab, and will start at least 30 minutes after 
completion of the nivolumab infusion. 
 
Ipilimumab may be diluted in 0.9% Sodium Chloride Solution or 5% Dextrose solution.  
 
Nivolumab may be diluted in 0.9% Sodium Chloride Solution. 
 
10.2.7 Adverse Events 
Based on data from the Phase I study, nivolumab in combination with ipilimumab has an 
acceptable safety profile in RCC. In summary, AEs were reported in 97.7% of subjects treated 
with nivolumab in combination with ipilimumab. The most frequently reported drug-related AEs 
in subjects treated with 3-mg/kg nivolumab + 1-mg/kg ipilimumab included fatigue (11 subjects, 
52.4%), rash (8 subjects, 38.1%), diarrhea (6 subjects, 28.6%), and pruritus (6 subjects, 28.6%); 
the majority were Grade 1-2. The most frequently reported drug-related AEs in subjects treated 
with 1-mg/kg nivolumab + 3-mg/kg ipilimumab included fatigue (16 subjects, 69.6%); nausea, 
ALT increased, AST increased (9 subjects each, 39.1%); and diarrhea (8 subjects, 34.8%). The 
majority were Grade 1-2. The majority of deaths were due to disease progression. No drug-


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 50 of 71 
related deaths have been reported to date. Please refer to the most current IB for a comprehensive 
list of AEs. 
 
11. 
ADVERSE EVENTS 
The descriptions and grading scales found in the NCI CTCAE v4.03 will be utilized for AE 
assessment throughout the life of the protocol. A copy of the CTCAE v4.03 criteria can be 
downloaded from the CTEP website at http://ctep.cancer.gov. All forms for AE/SAE recording 
and reporting can be found in the Study Procedure Manual or in the EDC system (Documents 
and Information Tab). 
 
11.1 
Definitions 
 
11.1.1 Adverse Event (AE) 
An AE is any untoward medical occurrence whether or not considered related to the study drug 
that appears to change in intensity during the course of the study. The following are examples of 
AEs:  
 Unintended or unfavorable sign or symptom 
 A disease temporally associated with participation in the protocol 
 An intercurrent illness or injury that impairs the well-being of the subject 
 
Abnormal laboratory values or diagnostic test results constitute AEs only if they induce clinical 
signs or symptoms or require treatment or further diagnostic tests   
 
Hospitalization for elective surgery or routine clinical procedures that are not the result of an AE 
(e.g., surgical insertion of central line) should not be recorded as an AE.  
 
Disease progression should not be recorded as an AE, unless it is attributable to the study 
regimen by the site investigator. 
 
11.1.2 Serious Adverse Event (SAE) 
A SAE is an adverse event that: 
 Results in death. NOTE: Death due to disease progression should not be reported as a 
SAE, unless it is attributable by the site investigator to the study drug(s) 
 Is life-threatening (defined as an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe) 
 Requires inpatient hospitalization for >24 hours or prolongation of existing 
hospitalization. NOTE: Hospitalization for anticipated or protocol specified procedures 
such as administration of chemotherapy, central line insertion, metastasis interventional 
therapy, resection of primary tumor, or elective surgery, will not be considered serious 
adverse events. 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly or birth defect 
 Is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical 
and scientific judgment, may jeopardize the subject or may require intervention (e.g., 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 51 of 71 
medical, surgical) to prevent one of the other serious outcomes listed in the definition 
above). Examples of such events include, but are not limited to, intensive treatment in an 
emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions 
not resulting in hospitalization; or the development of drug dependency or drug abuse. 
 
11.1.3 Unexpected Adverse Event 
For this study, an AE is considered unexpected when it varies in nature, intensity or frequency 
from information provided in the current IB, prescribing information or when it is not included in 
the informed consent document as a potential risk. Unexpected also refers to AEs that are 
mentioned in the IB as occurring with a class of drugs or are anticipated from the 
pharmacological properties of the drug, but are not specifically mentioned as occurring with the 
particular drug under investigation.   
 
11.1.4 Relatedness 
AEs will be categorized according to the likelihood that they are related to the study drug(s). 
Specifically, they will be categorized using the following terms:  
 
Unrelated 
Adverse Event is not related to the study drug(s)  
Unlikely 
Adverse Event is doubtfully related to the study drug(s)  
Possible 
Adverse Event may be related to the study drug(s)  
Probable 
Adverse Event is likely related to the study drug(s)  
Definite 
Adverse Event is clearly related to the study drug(s)  
 
11.1.5 Pregnancy 
If, following initiation of the study drugs, it is subsequently discovered that a subject is pregnant 
or may have been pregnant at the time of study drug exposure, including during at least 6 half 
lives after study drug administration, the study drug will be permanently discontinued in an 
appropriate manner (eg, dose tapering if necessary for subject safety).  
 
The site investigator must immediately notify HCRN who will then notify Worldwide Safety 
@BMS of this event via the HCRN Pregnancy Form in accordance with SAE reporting 
procedures. Follow-up information regarding the course of the pregnancy, including perinatal 
and neonatal outcome and, where applicable, offspring information must be reported on the 
HCRN Pregnancy Form. Any pregnancy that occurs in a female partner of a male study 
participant should be reported to HCRN who will then report it to BMS. Information on this 
pregnancy will be collected on the HCRN Pregnancy Form. 
 
11.1.6 Overdose 
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as a SAE. 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 52 of 71 
11.2 
Reporting 
 
11.2.1 Adverse Events  
 AEs will be recorded from time of signed informed consent until 100 days after 
discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever 
occurs first.  
 AEs will be recorded regardless of whether or not they are considered related to the study 
drug(s).   
 All AEs will be recorded in the subject’s medical record and on the appropriate study 
specific eCRF form within the EDC system. 
 AEs considered related to study drug(s) will be followed until resolution to Grade ≤ 1 or 
baseline, deemed clinically insignificant, and/or until a new anti-cancer treatment starts, 
whichever occurs first. 
 
11.2.2 Serious Adverse Events (SAEs) 
 
11.2.2.1 
Site Requirements for Reporting SAEs to HCRN 
 SAEs will be reported from time of signed informed consent until 100 days after 
discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever 
occurs first.  
 SAEs will be reported on the SAE Submission Form within 1 business day of discovery 
of the event.   
 SAEs include events related and unrelated to the study drug(s).  
 All SAEs will be recorded in the subject’s medical record and on the appropriate study 
specific eCRF form within EDC system.   
 All SAEs regardless of relation to study drug will be followed until resolution to ≤ Grade 
1 or baseline and/or deemed clinically insignificant and/or until a new anti-cancer 
treatment starts, whichever occurs first. 
 
The site will submit the completed SAE Submission Form to HCRN within 1 business day of 
discovery of the event. The form may be submitted to HCRN electronically to 
safety@hoosiercancer.org. The site investigator is responsible for informing the IRB and/or other 
local regulatory bodies as per local requirements.  The original copy of the SAE Submission 
Form and the email correspondence must be kept within the study file at the study site. 
 
Once the SAE has resolved (see resolution guidelines listed in 11.2.2.1), sites must submit a 
follow-up SAE Submission Form within a reasonable timeframe to HCRN electronically to 
safety@hoosiercancer.org.   
 
11.2.2.2 
HCRN Requirements for Reporting SAEs to BMS  
HCRN will report all SAEs to BMS within 1 business day of receipt of the SAE Submission 
Form from a site. Follow-up information will be provided to BMS as it is received from site.  
Contact information for sending SAE information to BMS below: 
 
SAE Email Address:  Worldwide.Safety@BMS.com 
SAE Facsimile Number:  609-818-3804 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 53 of 71 
HCRN and the Sponsor-investigator will ensure that all SAEs in the clinical database are 
reported to BMS and any applicable health authority during the conduct of the study. This 
reconciliation will occur at least quarterly and be initiated by HCRN on behalf of the sponsor-
investigator. HCRN will request on behalf of the sponsor-investigator a reconciliation report 
from: aepbusinessprocess@bms.com. During reconciliation, any events found to not be reported 
previously to BMS must be sent to Worldwide.Safety@BMS.com.  
 
11.3 
Sponsor-Investigator Responsibilities  
HCRN will send a SAE summary to the sponsor-investigator within 1 business day of receipt of 
SAE Submission Form from a site.  The sponsor-investigator will promptly review the SAE 
summary and assess for expectedness and relatedness.   
 
11.4 
HCRN Responsibilities to FDA 
HCRN will manage the Investigational New Drug Application (IND) associated with this 
protocol on behalf of the sponsor-investigator. HCRN will cross-reference this submission to the 
BMS’s parent IND at the time of submission. Additionally, HCRN will submit a copy of these 
documents to BMS at the time of submission to FDA. 
 
HCRN will be responsible for all communication with the FDA in accordance with 21CFR312 
including but not limited to the 7 and 15 Day Reports, as well as an Annual Progress Report. 
Additionally, HCRN will submit a copy of these reports to BMS at the time of submission to 
FDA. 
 
11.5 
IND Safety Reports Unrelated to this Trial 
BMS will provide to HCRN IND safety reports from external studies that involve the study 
drug(s) per their guidelines.  HCRN will forward safety reports to the sponsor-investigator who 
will review these reports and determine if revisions are needed to the protocol or consent. HCRN 
will forward these reports to participating sites within 1 business day of receiving the sponsor-
investigator’s review.  Based on the sponsor-investigator’s review, applicable changes will be 
made to the protocol and informed consent document (if required).  All IND safety reports will 
also be made available to sites via the EDC system.    
 
Upon receipt from HCRN, site investigators (or designees) are responsible for submitting these 
safety reports to their respective IRBs, as per their IRB policies. 
 
12. 
STATISTICAL METHODS 
 
12.1 
Part A Primary Endpoint 
The primary focus of this trial will be in the evaluation of PD-L1 to predict outcome and, also, 
secondarily to use the PRP model as a basis for outcome prediction. We expect that about 45% 
(or 54 expected) patients will have 0% PD-L1 and roughly 15% (or 18 expected) patients will 
express PD-L1 > 20%, which, given the sample size of 120 ccRCC patients provides 90% power 
using a 0.05 level two-sided test to test the hypothesis that PD-L1 >20% will be associated with 
significantly improved 1-year PFS rate for patients treated with PD-1 blockade (55% vs 13% 
taken as a binomial quantity). Considering the four groups of PD-L1 expression (0%, 1-5%, 5-
20%, >20%), and with an expected patient allocation within groups of (45%, 25%, 15%, 15%), 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 54 of 71 
the Cochran-Armitage test gives at least 90% power to detect a trend in 1-year PFS of (13%, 
19%, 35%, 55%) using a two-sided 0.05 level test for trend. Modest changes in the proportions 
of patients in the variouse PD-L1 categories will not substantially affect the power. For example, 
if the distribution across PD-L1 categories is [25%, 25%, 25%, 25%] rather than the anticipated 
[45%, 25%, 15%, 15%] the power for the trend test remains greater than 90%. 
 
As a secondary objective, we will apply the PRP model, developed in the DF/HCC Kidney 
SPORE Project 4, to assign each patient a probability of having PFS >1 year.  The validity of the 
model will be assessed by the Brier score as well as via evaluation of the AUC.  The exact 
distribution is unknown, but assuming an overall 1-year PFS of 28% and that 40% of patients are 
expected to be “positive” by the PRP model, 120 ccRCC patients give 90% power to detect a 
29% higher 1-year PFS between 48 positive patients and 72 negative patients (via Fisher’s exact 
test and assuming a difference in PFS of 46% vs 17%). All testing above will be done at 1-sided 
α=0.025. The specific distributional breakdowns are unknown but the power is relatively robust. 
For example, if the split between positive and negative is more even (50/50) then power for the 
above difference in 1-yr PFS remains over 90%. If the actual difference in 1-yr PFS is smaller 
than anticipated for example 25% (44% vs 19%) then the test will still have at least 80% power. 
 
12.2 
Part B 
Clear cell patients who reach best response of SD at 48 weeks or who experience progression 
will be offered the opportunity to enroll in the second component of the study, Part B, continued 
treatment with the addition of ipilimumab. The primary endpoint of this portion of the trial will 
be objective response (CR or PR) taking as baseline tumor measurements at the patient’s start of 
Part B. It is expected that roughly one-half of the Part A patients will be eligible for and choose 
to enroll in Part B, or roughly 60 total patients. A two-stage design will be used for this portion 
of the study where in the first cohort 29 patients will be accrued, treated and evaluated for 
response in order to provide guidance on whether to continue to enroll the entire cohort of 60 
patients. The first stage analysis will be conducted without pausing accrual to Part B. If among 
the first 29 Part B patients there are at least 2 responses, there will be sufficient evidence to 
continue recruitment to Part B. With a true uninteresting response rate of 5%, there is a 57% 
chance of declaring the regimen uninteresting; however, with an interesting response rate of 
20%, there is greater than 95% chance of continuing. If after enrollment of 60 patients there are 
at least 11 total responses, the lower limit on the 90% confidence interval for the true response 
rate will exclude 10% (ie, the 95% confidence interval will range from 10.6% to 28.5%, adjusted 
for the two-stage design). With 18 total responses, the 90% confidence interval on the true 
objective response proportion will exclude 20% (it, the confidence interval will range from 
20.4% to 41.2%, adjusted for the two-stage design).  
 
12.3 
Non-clear cell (ncc) RCC: Part A 
Subjects (comprising a heterogeneous group of histologies) will also be enrolled in the trial, at an 
accrual rate that is expected to be 33% that of clear cell patients. Therefore, an expected cohort 
of 40 nccRCC patients will be enrolled in the trial and analyzed separately for evidence of anti-
tumor activity, principally focusing on overall response rate (CR or PR). With 40 patients, the 
95% confidence interval on the true objective response proportion will be no wider than 32.4 
percentage points and the probability of observing five or more responses under the hypothesis 
that the true response rate is 0.20 is at least 92%, hence there is high power to detect responses in 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 55 of 71 
this cohort should the true response rate be interesting. Other endpoints of interest in this group 
of patients will include rates of SD and PFS at 1-year. 
 
12.4 
NccRCC patients: Part B  
These subjects will also be available to enroll in Part B of the study.  An estimated 20 patients 
will be enrolled and response rates in this resistant population will be reported.  If no responses 
are seen in the first 14 patients that response rate will be deemed uninteresting. If any confirmed 
responses are seen accrual of ncc patients will continue for all eligible patients completing Part 
A. 
 
12.5 
Single Cell RNA seq Correlative (ccRCC)  
At this time, 10 fresh frozen baseline tumor specimens and 3 pairs of specimens have been 
collected with an additional patient likely to be collected before accrual of the original 120 
patients is complete. Therefore, fourteen additional patients are to be enrolled to collect fresh 
frozen specimens necessary to provide 25 baseline and 15 paired baseline and resistant fresh 
frozen samples to be used for single cell RNAseq experiments aimed at identifying factors 
associated to resistance as outlined in the DOD Translational Research Partnership grant to Drs. 
Atkins and Wu. Assuming 15 patients non-responsive to nivo and up to 10 patients responding, 
comparisons of any quantitative expression level using a 0.05 level two-sided two-group t-test 
will have 80% power to detect at least a 1.2 SD shift in means using baseline samples. With 15 
paired samples at baseline and at confirmed radiologic progression among the non-responders, 
there is at least 80% power to detect a change in expression of 0.78 SD in any markers using a 
two-sided 0.05 level paired t-test. For two binary markers that are at least 50% discordant there is 
at least 80% power to detect a +/- versus -/+ discordance of at least 47% using a two-sided 0.05 
level McNemar’s test. 
 
12.6 
Study Design 
This is a phase II open-labeled study or single agent nivolumab involving two distinct groups of 
systemic treatment naïve patients – those with either metastatic clear cell (cc) or non-clear cell 
(ncc) RCC. One hundred and twenty patients will be accrued to the ccRCC group and up to 40 to 
the nccRCC group. Eligible patients will be enrolled at time of documented progression or 
prolonged SD, into Part B of the study, which involves the addition of ipilimumab to nivolumab. 
Part B will constitute a separate open-labeled phase II study with baseline parameters being reset 
at time of subject enrollment. With multicenter accrual of 6-7 patients per month, the study 
should accrue in 2 years.   
 
12.7 
Endpoints 
 
12.7.1 Definition of Primary Endpoint 
 PFS is defined as the time from Day 1 of treatment until the criteria for disease 
progression is met as defined by RECIST 1.1 or death as a result of any cause.  
 The primary focus of this trial will be in the evaluation of PD-L1 expression levels to 
predict outcome. We expect that about 45% (or 54 expected) patients will have 0% PD-
L1 and roughly 15% (or 18 expected) patients will express PD-L1 > 20%, which, given 
the sample size of 120 ccRCC patients provides 90% power using a 0.05 level two-sided 
test to test the hypothesis that PD-L1 >20% will be associated with significantly 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 56 of 71 
improved 1-year PFS rate for patients treated with PD-1 blockade (55% vs 13% taken as 
a binomial quantity).  
 
12.7.2 Secondary Endpoints 
 Apply the PRP model, developed in the DF/HCC Kidney SPORE Project 4, to assign 
each patient a probability of having PFS > 1 year. 
 The endpoint for Part B (addition of ipilimumab) will be objective response (CR or PR) 
taking as baseline tumor measurements at the patient’s start of Part B. 
 An expected cohort of 40 nccRCC patients will be enrolled in the trial and analyzed 
separately for evidence of anti-tumor activity, principally focusing on overall response 
rate (CR or PR). 
 Toxicity by CTCAE criteria of nivolumab monotherapy in treatment naïve patients with 
cc and nccRCC.  
 
12.8 
Analysis Datasets 
The primary analysis for both Part A and Part B will be the enrolled population comprising all 
subjects who meet eligibility criteria and are registered onto the study.  
 
12.9 
Assessment of Safety 
This will be performed in all subjects that contribute data to the safety analysis e.g any subject 
who receives at least one dose of treatment on Part A of this protocol. The safety analysis for 
Part B will be considered separately and will include any subject who receives at least one dose 
of treatment on Part B. Safety will be assessed using the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE), v4.03.  In addition, Immune 
Related Adverse events IrAE will also be recorded. 
 
12.10 Assessment of Efficacy 
All subjects with ccRCC who are registered on study will be assessed for progression free 
survival in order to determine the PFS rate at 1 year.  Those patients who cross over to Part B of 
the study and have measurable disease will be assessed for tumor response using RECIST 1.1 
with the pre-Part B tumor measurements serving as baseline.   
 
All subjects with nccRCC who are registered on study will be assessed for tumor response using 
traditional RECIST 1.1 criteria both for Part A and Part B (if they have measurable disease at 
time of crossover).  
 
12.11 Interim Analysis/Criteria for Stopping Study 
A two-stage design will be used for Part B for the ccRCC population. In this study the first 
cohort 29 patients will be accrued, treated and evaluated for response in order to provide 
guidance on whether to continue to enroll the entire cohort of 60 patients. The first stage analysis 
will be conducted without pausing accrual to Part B. If among the first 29 Part B patients there 
are at least 2 responses, there will be sufficient evidence to continue recruitment to Part B. With 
a true uninteresting response rate of 5%, there is a 57% chance of declaring the regimen 
uninteresting; however, with an interesting response rate of 20%, there is greater than 95% 
chance of continuing.  
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 57 of 71 
13. 
TRIAL MANAGEMENT 
 
13.1 
Data and Safety Monitoring Plan (DSMP) 
The study will be conducted with guidance from the Georgetown-Lombardi Comprehensive 
Cancer Center’s (Georgetown LCCC) DSMP.  
 
HCRN oversight activities include: 
 Review all adverse events requiring expedited reporting as defined in the protocol 
 Provide trial accrual progress, safety information and data summary reports to the 
sponsor-investigator  
 Submit data summary reports to the lead institution Data Safety Monitoring Committee 
per Georgetown LCCC’s DSMP. 
 Submit data summary reports to the DSMC for review per DSMC SOP 
 
13.2 
Georgetown-Lombardi Comprehensive Cancer Center’s Data Safety Monitoring 
Committee 
HCRN will provide the following for the Georgetown LCCC’s DSMC to review: 
 Adverse event summary report 
 Monitoring reports and audit results if applicable 
 Data related to stopping/decision rules described in study design 
 Study accrual patterns  
 Protocol deviations 
 
The Georgetown LCCC DSMC will review study data every quarter.  Documentation of DSMC 
reviews will be provided to sponsor-investigator and HCRN.  Issues of immediate concern by the 
DSMC will be brought to the attention of the sponsor-investigator and other regulatory bodies as 
appropriate.  The sponsor-investigator will work with HCRN to address the DSMC’s concerns.    
 
13.3 
Data Quality Oversight Activities 
Remote validation of the EDC system data will be completed on a continual basis throughout the 
life cycle of the study.  Automated edit check listings will be used to generate queries in the EDC 
system and transmitted to the site to address in a timely fashion. Corrections will be made by the 
study site personnel. 
 
Monitoring visits to the trial sites may be made periodically during the trial to ensure key aspects 
of the protocol are followed. For cause audits may be performed as necessary. During onsite 
monitoring visits, source documents will be reviewed for verification of agreement with data 
entered into the EDC system.  It is important for the site investigator and their relevant personnel 
to be available for a sufficient amount of time during the monitoring visits or audit, if applicable. 
The site investigator and institution guarantee access to source documents by HCRN or its 
designee. 
 
The trial site may also be subject to quality assurance audit, as well as inspection by appropriate 
regulatory agencies. 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 58 of 71 
13.4 
Compliance with Trial Registration and Results Posting Requirements 
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the sponsor-investigator of the trial 
is solely responsible for determining whether the trial and its results are subject to the 
requirements for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov. All 
results of primary and secondary objectives must be posted to CT.gov within a year of 
completion.  The sponsor-investigator has delegated responsibility to HCRN for registering the 
trial and posting the results on clinicaltrials.gov. Information posted will allow subjects to 
identify potentially appropriate trials for their disease conditions and pursue participation by 
calling a central contact number for further information on appropriate trial locations and study 
site contact information.   
 
14. 
DATA HANDLING AND RECORD KEEPING 
 
14.1 
Data Management 
HCRN will serve as the Clinical Research Organization for this trial. Data will be collected 
through a web based clinical research platform, a system compliant with Good Clinical Practices 
and Federal Rules and Regulations.  HCRN personnel will coordinate and manage data for 
quality control assurance and integrity. All data will be collected and entered into the EDC 
system by study site personnel from participating institutions.   
 
14.2 
Case Report Forms and Submission 
Generally, clinical data will be electronically captured in the EDC system and correlative results 
will be captured in the EDC system or other secure database(s). If procedures on the study 
calendar are performed for standard of care, at minimum, that data will be captured in the source 
document. Select standard of care data will also be captured in the EDC system, according to 
study-specific objectives.  
 
The completed dataset is the sole property of the sponsor-investigator’s institution and should 
not be exported to third parties, except for authorized representatives of appropriate 
Health/Regulatory Authorities, without permission from the sponsor-investigator and HCRN. 
 
14.3 
Record Retention 
To enable evaluations and/or audits from Health Authorities/HCRN, the site investigator agrees 
to keep records, including the identity of all subjects (sufficient information to link records; e.g., 
hospital records), all original signed informed consent forms, copies of all source documents, and 
detailed records of drug disposition. All source documents are to remain in the subject’s file and 
retained by the site investigator in compliance with the site contract with HCRN.  No records 
will be destroyed until HCRN confirms destruction is permitted. 
 
14.4 
Confidentiality 
There is a slight risk of loss of confidentiality of subject information. All records identifying the 
subjects will be kept confidential and, to the extent permitted by the applicable laws and/or 
regulations, will not be made publicly available. Information collected will be maintained on 
secure, password protected electronic systems. Paper files that contain personal information will 
be kept in locked and secure locations only accessible to the study site personnel.  


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 59 of 71 
Subjects will be informed in writing that some organizations including the sponsor-investigator 
and his/her research associates, HCRN, BMS, IRB, or government agencies, like the FDA, may 
inspect their medical records to verify the information collected, and that all personal 
information made available for inspection will be handled in strictest confidence and in 
accordance with local data protection laws. 
 
If the results of the study are published, the subject’s identity will remain confidential. 
 
15 
ETHICS 
 
15.1 
Institutional Review Board (IRB) Approval 
The final study protocol and the final version of the informed consent form must be approved in 
writing by an IRB. The site investigator must submit written approval by the IRB to HCRN 
before he or she can enroll subjects into the study.   
 
The site investigator is responsible for informing the IRB of any amendment to the protocol in 
accordance with local requirements. In addition, the IRB must approve all advertising used to 
recruit subjects for the study. The protocol must be re-approved by the IRB, as local regulations 
require.  
 
Progress reports and notifications of serious and unexpected adverse events will be provided to 
the IRB according to local regulations and guidelines. 
 
15.2 
Ethical Conduct of the Study 
The study will be performed in accordance with ethical principles originating from the 
Declaration of Helsinki.  Conduct of the study will be in compliance with ICH Good Clinical 
Practice, and with all applicable federal (including 21 CFR parts 56 & 50), state, or local laws. 
 
15.3 
Informed Consent Process 
The site investigator will ensure the subject is given full and adequate oral and written 
information about the nature, purpose, possible risks and benefits of the study. Subjects must 
also be notified they are free to discontinue from the study at any time. The subject should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
 
The subject’s signed and dated informed consent must be obtained before conducting any 
procedure specifically for the study. The site investigator must store the original, signed 
informed consent form. A copy of the signed informed consent form must be given to the 
subject.  
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 60 of 71 
16 REFERENCES 
 
1. Znaor, A., et al., International variations and trends in renal cell carcinoma incidence and 
mortality. Eur Urol, 2015. 67(3): p. 519-30. 
2. Society, A.C. Kidney Cancer (Adult) - Renal Cell Carcinoma. 2016 February 28, 2016]; 
Available from: http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-
adult-key-statistics. 
3. Gupta, K., et al., Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma 
(mRCC): a literature review. Cancer Treat Rev, 2008. 34(3): p. 193-205. 
4. Yao, M., et al., VHL tumor suppressor gene alterations associated with good prognosis in 
sporadic clear-cell renal carcinoma. Journal of the National Cancer Institute, 2002. 94(20): p. 
1569-1575. 
5. Oda, H. and R. Machinami, Sarcomatoid renal cell carcinoma. A study of its proliferative 
activity. Cancer, 1993. 71(7): p. 2292-2298. 
6. Cancer Genome Atlas Research, N., et al., Comprehensive Molecular Characterization of 
Papillary Renal-Cell Carcinoma. N Engl J Med, 2016. 374(2): p. 135-45. 
7. Sharpe, A.H., et al., The function of programmed cell death 1 and its ligands in regulating 
autoimmunity and infection. Nat Immunol, 2007. 8(3): p. 239-45. 
8. Bristol-Myers Squibb Company, Nonclinical Study Report: Medarex Study No. MDX1106-
025-R. In vitro characterization of a fully human anti-PD-1 monoclonal antibody. Document 
Control No. 930046580, 2006. 
9. Bristol-Myers Squibb Company, Nonclinical Study Report: Medarex Study No. MDX1106-
028-R. Binding and blocking characteristics of chimeric anti-mouse PD-1 antibody, 4H2. 
Document Control No. 930046578., 2007. 
10. Velu, V., et al., Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 2009. 
458(7235): p. 206-10. 
11. Bristol-Myers Squibb Company, Nonclinical Study Report: Medarex Study No. MDX1106-
032-R. Effects of anti-PD-1 administration on staged MC38 tumors in mice. Document 
Control No. 930046566., 2006. 
12. Wang, C., et al., In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-
936558, and in vivo toxicology in non-human primates. Cancer Immunol Res, 2014. 2(9): p. 
846-56. 
13. Bristol-Myers Squibb Company, Nonclinical Study Report: Study No. DN12123; BMS-
986016 and BMS-936558: Four-week intravenous combination toxicity study in monkeys 
with a 6-week recovery. Document Control No. 930070016, 2013. 
14. Bristol-Myers Squibb Company, BMS-936558: Intravenous Study of pre- and postnatal 
development in cynomolgus monkeys with a 6-month postnatal evaluation. Final report for 
Study DN12001. . Document Control No. 930073964. 
15. Habicht, A., et al., A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance. 
The Journal of Immunology, 2007. 179(8): p. 5211-5219. 
16. Brahmer, J.R., et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in 
refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic 
correlates. J Clin Oncol, 2010. 28(19): p. 3167-75. 
17. Topalian, S.L., et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 
N Engl J Med, 2012. 366(26): p. 2443-54. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 61 of 71 
18. McDermott, D.F., et al., Survival, durable response, and long-term safety in patients with 
previously treated advanced renal cell carcinoma receiving nivolumab. Journal of Clinical 
Oncology, 2015: p. JCO. 2014.58. 1041. 
19. Motzer, R.J., et al., Nivolumab for Metastatic Renal Cell Carcinoma: Results of a 
Randomized Phase II Trial. J Clin Oncol, 2015. 33(13): p. 1430-7. 
20. Motzer, R.J., et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N 
Engl J Med, 2015. 373(19): p. 1803-13. 
21. Choueiri, T.K., et al. Immunomodulatory activity of nivolumab in previously treated and 
untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a 
randomized clinical trial. in ASCO Annual Meeting Proceedings. 2014. 
22. Larkin, J., et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated 
Melanoma. N Engl J Med, 2015. 373(1): p. 23-34. 
23. Postow, M.A., et al., Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
N Engl J Med, 2015. 372(21): p. 2006-17. 
24. Hammers, H., et al., 1050OPhase I study of nivolumab in combination with ipilimumab in 
metastatic renal cell carcinoma (MRCC). Annals of Oncology, 2014. 25(suppl 4): p. iv361-
iv362. 
25. Motzer R. J., et al, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell 
Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. 
Epub 2018 Mar 21. 
26. Callea, M., et al., Differential Expression of PD-L1 between Primary and Metastatic Sites in 
Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res, 2015. 3(10): p. 1158-64. 
27. Choueiri, T.K., et al., PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol, 
2014. 25(11): p. 2178-84. 
28. Motzer, R.J., et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl 
J Med, 2007. 356(2): p. 115-24. 
29. McDermott, D.F., et al., Randomized phase III trial of high-dose interleukin-2 versus 
subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J 
Clin Oncol, 2005. 23(1): p. 133-41. 
30. Keir, M.E., et al., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008. 
26: p. 677-704. 
31. Keir, M.E., G.J. Freeman, and A.H. Sharpe, PD-1 regulates self-reactive CD8+ T cell 
responses to antigen in lymph nodes and tissues. J Immunol, 2007. 179(8): p. 5064-70. 
32. Dong, H., et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism 
of immune evasion. Nat Med, 2002. 8(8): p. 793-800. 
33. Blank, C., et al., Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell 
responses in vitro. Int J Cancer, 2006. 119(2): p. 317-27. 
34. Ahmadzadeh, M., et al., Tumor antigen-specific CD8 T cells infiltrating the tumor express 
high levels of PD-1 and are functionally impaired. Blood, 2009. 114(8): p. 1537-44. 
35. Thompson, R.H., et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of 
tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A, 2004. 
101(49): p. 17174-9. 
36. Brahmer, J.R., et al., Safety and activity of anti-PD-L1 antibody in patients with advanced 
cancer. N Engl J Med, 2012. 366(26): p. 2455-65. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 62 of 71 
37. Cho, D.C., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered 
PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). in ASCO Annual 
Meeting Proceedings. 2013. 
38. McDermott, D.F., et al., Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) 
in patients with previously treated metastatic renal cell carcinoma (mRCC). J Clin Oncol, 
2012. 30(15 Suppl): p. 4505. 
39. Callahan, M.K., et al. Peripheral and tumor immune correlates in patients with advanced 
melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and 
ipilimumab. in ASCO Annual Meeting Proceedings. 2013. 
40. Grosso, J., et al. Association of tumor PD-L1 expression and immune biomarkers with 
clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-
1; BMS-936558; ONO-4538). in ASCO Annual Meeting Proceedings. 2013. 
41. Kim, J.M. and D.S. Chen, Immune escape to PD-L1/PD-1 blockade: seven steps to success 
(or failure). Ann Oncol, 2016. 
42. Serra-Bellver, P., S. Valpione, and P. Lorigan, Sequential immunotherapy regimens—expect 
the unexpected. The Lancet Oncology, 2016. 
43. Simpson, T.R., et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-
defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med, 2013. 210(9): p. 
1695-710. 
44. Hamid, O., et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. 
N Engl J Med, 2013. 369(2): p. 134-44. 
45. Gandhi, L., et al., Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small 
cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression. 
Cancer Research, 2014. 74(19 Supplement): p. CT105-CT105. 
46. Wolchok, J.D., et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 
2013. 369(2): p. 122-33. 
47. Callea, M., et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and 
their metastases. in ASCO Annual Meeting Proceedings. 2014. 
48. Choueiri, T.K., et al., Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell 
Carcinoma. Clin Cancer Res, 2016. 
49. Kondo, T., et al., Favorable prognosis of renal cell carcinoma with increased expression of 
chemokines associated with a Th1-type immune response. Cancer Sci, 2006. 97(8): p. 780-6. 
50. Ji, R.R., et al., An immune-active tumor microenvironment favors clinical response to 
ipilimumab. Cancer Immunol Immunother, 2012. 61(7): p. 1019-31. 
51. Fritsch, E.F., et al., HLA-binding properties of tumor neoepitopes in humans. Cancer 
Immunol Res, 2014. 2(6): p. 522-9. 
52. Rajasagi, M., et al., Systematic identification of personal tumor-specific neoantigens in 
chronic lymphocytic leukemia. Blood, 2014. 124(3): p. 453-62. 
53. Snyder, A., et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N 
Engl J Med, 2014. 371(23): p. 2189-99. 
54. Van Allen, E.M., et al., Genomic correlates of response to CTLA-4 blockade in metastatic 
melanoma. Science, 2015. 350(6257): p. 207-11. 
55. Le, D.T., et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 
2015. 372(26): p. 2509-20. 
56. Rizvi, N.A., et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 
blockade in non-small cell lung cancer. Science, 2015. 348(6230): p. 124-8. 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 63 of 71 
57. Rosenberg, J.E., et al., Atezolizumab in patients with locally advanced and metastatic 
urothelial carcinoma who have progressed following treatment with platinum-based 
chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016. 387(10031): p. 1909-
20. 
58. McDermott, D.F., et al., Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in 
Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune 
Correlates From a Phase Ia Study. J Clin Oncol, 2016. 34(8): p. 833-42. 
59. Seliger, B., Molecular mechanisms of MHC class I abnormalities and APM components in 
human tumors. Cancer Immunol Immunother, 2008. 57(11): p. 1719-26. 
60. Campoli, M. and S. Ferrone, HLA antigen changes in malignant cells: epigenetic 
mechanisms and biologic significance. Oncogene, 2008. 27(45): p. 5869-85. 
61. Garrido, F., T. Cabrera, and N. Aptsiauri, "Hard" and "soft" lesions underlying the HLA class 
I alterations in cancer cells: implications for immunotherapy. Int J Cancer, 2010. 127(2): p. 
249-56. 
62. Sakuishi, K., et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and 
restore anti-tumor immunity. J Exp Med, 2010. 207(10): p. 2187-94. 
63. Woo, S.R., et al., Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-
cell function to promote tumoral immune escape. Cancer Res, 2012. 72(4): p. 917-27. 
64. Goding, S.R., et al., Restoring immune function of tumor-specific CD4+ T cells during 
recurrence of melanoma. J Immunol, 2013. 190(9): p. 4899-909. 
65. Jing, W., et al., Combined immune checkpoint protein blockade and low dose whole body 
irradiation as immunotherapy for myeloma. J Immunother Cancer, 2015. 3(1): p. 2. 
66. Bu, X., K.M. Mahoney, and G.J. Freeman, Learning from PD-1 Resistance: New 
Combination Strategies. Trends Mol Med, 2016. 22(6): p. 448-51. 
67. Gerlinger, M., et al., Genomic architecture and evolution of clear cell renal cell carcinomas 
defined by multiregion sequencing. Nat Genet, 2014. 46(3): p. 225-33. 
68. Hugo, W., et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in 
Metastatic Melanoma. Cell, 2016. 165(1): p. 35-44. 
69. Stadler, Z.K., et al., Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers 
Using Mutational Load in Next-Generation Sequencing Panels. J Clin Oncol, 2016. 
70. Van Allen - Genomic correlates of CTLAi response in melanoma (Science 2015).pdf. 
71. Cancer Genome Atlas Research, N., Comprehensive molecular characterization of clear cell 
renal cell carcinoma. Nature, 2013. 499(7456): p. 43-9. 
 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 64 of 71 
 
17. 
APPENDIX A 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 65 of 71 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 66 of 71 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 67 of 71 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 68 of 71 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 69 of 71 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 70 of 71 
 
 
 


Clinical Study Protocol 
HCRN GU16-260 
Version Date: 25MAR2021 
Confidential 
Page 71 of 71